<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Therap Adv Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Therap Adv Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">TAG</journal-id><journal-id journal-id-type="hwp">sptag</journal-id><journal-title-group><journal-title>Therapeutic Advances in Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1756-283X</issn><issn pub-type="epub">1756-2848</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40012837</article-id><article-id pub-id-type="pmc">PMC11863242</article-id><article-id pub-id-type="doi">10.1177/17562848251323004</article-id><article-id pub-id-type="publisher-id">10.1177_17562848251323004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Tryptophan metabolites profile predict remission with dietary therapy in pediatric Crohn&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sigall Boneh</surname><given-names>Rotem</given-names></name><xref rid="fn1-17562848251323004" ref-type="author-notes">*</xref><aff id="aff1-17562848251323004">Department of Pediatric Gastroenterology and Nutrition, Emma Children&#x02019;s Hospital, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><aff id="aff2-17562848251323004">Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><aff id="aff3-17562848251323004">Pediatric Gastroenterology and Nutrition Unit, The E. Wolfson Medical Center, Holon, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>van der Kruk</surname><given-names>Nikki</given-names></name><xref rid="fn1-17562848251323004" ref-type="author-notes">*</xref><aff id="aff4-17562848251323004">Department of Pediatric Gastroenterology and Nutrition, Emma Children&#x02019;s Hospital, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><aff id="aff5-17562848251323004">Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Wine</surname><given-names>Eytan</given-names></name><aff id="aff6-17562848251323004">Division of Pediatric Gastroenterology, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Verburgt</surname><given-names>Charlotte M.</given-names></name><aff id="aff7-17562848251323004">Department of Pediatric Gastroenterology and Nutrition, Emma Children&#x02019;s Hospital, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>de Meij</surname><given-names>Tim G. J.</given-names></name><aff id="aff8-17562848251323004">Department of Pediatric Gastroenterology and Nutrition, Emma Children&#x02019;s Hospital, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>L&#x000f6;wenberg</surname><given-names>Mark</given-names></name><aff id="aff9-17562848251323004">Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Gecse</surname><given-names>Krisztina B.</given-names></name><aff id="aff10-17562848251323004">Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0125-0680</contrib-id><name><surname>Wierdsma</surname><given-names>Nicolette</given-names></name><aff id="aff11-17562848251323004">Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Derikx</surname><given-names>Joep P. M.</given-names></name><aff id="aff12-17562848251323004">Department of Pediatric Surgery, Emma Children&#x02019;s Hospital, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>de Jonge</surname><given-names>Wouter J.</given-names></name><aff id="aff13-17562848251323004">Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><aff id="aff14-17562848251323004">Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><aff id="aff15-17562848251323004">Department of Surgery, University of Bonn, Bonn, Germany</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Haens</surname><given-names>Geert</given-names></name><aff id="aff16-17562848251323004">Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2095-371X</contrib-id><name><surname>Ghiboub</surname><given-names>Mohammed</given-names></name><xref rid="fn2-17562848251323004" ref-type="author-notes">#</xref><xref rid="corresp1-17562848251323004" ref-type="corresp"/><aff id="aff17-17562848251323004">Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, Amsterdam University, Meibergdreef 69, Amsterdam 1105 BK, The Netherlands</aff><aff id="aff18-17562848251323004">Department of Pediatric Surgery, Emma Children&#x02019;s Hospital, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Van Limbergen</surname><given-names>Johan E.</given-names></name><xref rid="fn2-17562848251323004" ref-type="author-notes">#</xref><aff id="aff19-17562848251323004">Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, Amsterdam University, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands</aff><aff id="aff20-17562848251323004">Department of Pediatric Gastroenterology and Nutrition, Emma Children&#x02019;s Hospital, Amsterdam University Medical Centers, Amsterdam University, Amsterdam, The Netherlands</aff><aff id="aff21-17562848251323004">Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, The Netherlands</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib></contrib-group><author-notes><corresp id="corresp1-17562848251323004">
<email>m.ghiboub@amsterdamumc.nl</email>
</corresp><corresp id="corresp2-17562848251323004">
<email>j.e.vanlimbergen@amsterdamumc.nl</email>
</corresp><fn fn-type="other" id="fn1-17562848251323004"><label>*</label><p>Joint first authors.</p></fn><fn fn-type="other" id="fn2-17562848251323004"><label>#</label><p>Joint senior authors.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>18</volume><elocation-id>17562848251323004</elocation-id><history><date date-type="received"><day>21</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>5</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-17562848251323004"><title>Background:</title><p>Crohn&#x02019;s disease (CD) exclusion diet combined with partial enteral nutrition (CDED&#x02009;+&#x02009;PEN) or exclusive enteral nutrition (EEN) is effective in inducing remission in mild-to-moderate pediatric CD. Although CDED&#x02009;+&#x02009;PEN is better tolerated and has higher compliance compared to EEN, a subset of patients does not achieve remission. Diet-induced remission is shown to be positively associated with specific changes in tryptophan-metabolites.</p></sec><sec id="section2-17562848251323004"><title>Objectives:</title><p>To investigate whether the abundance of baseline fecal tryptophan-metabolites predicts dietary therapy outcomes in pediatric CD.</p></sec><sec id="section3-17562848251323004"><title>Design:</title><p>Diagnostic accuracy study and secondary analysis of previously conducted Randomized Controlled Trial (RCT).</p></sec><sec id="section4-17562848251323004"><title>Methods:</title><p>Twenty-six patients from previously performed RCT of mild-to-moderate pediatric CD were included. The patients were classified as having clinical remission (R) (<italic toggle="yes">n</italic>&#x02009;=&#x02009;19 in total; CDED&#x02009;+&#x02009;PEN&#x02009;=&#x02009;10 and to EEN&#x02009;=&#x02009;9) or No-Remission (NR) (<italic toggle="yes">n</italic>&#x02009;=&#x02009;7 in total; CDED&#x02009;+&#x02009;PEN&#x02009;=&#x02009;3 and EEN&#x02009;=&#x02009;4) following 6&#x02009;weeks of therapy, based on the Pediatric Crohn&#x02019;s Disease Activity Index score (&#x02a7d;10&#x02009;=&#x02009;remission). We performed a targeted quantitative analysis of 21 tryptophan-metabolites in baseline (<italic toggle="yes">t</italic>&#x02009;=&#x02009;0) fecal samples from both groups, utilizing liquid chromatography coupled with quadrupole mass spectrometry. Receiver operator characteristic curve (ROC) and random forest analysis (RFA) were used to assess the predictive power of fecal tryptophan-metabolites for dietary outcomes at baseline. Ratios of tryptophan-metabolites were compared to investigate different downstream tryptophan pathways.</p></sec><sec id="section5-17562848251323004"><title>Results:</title><p>Baseline fecal kynurenine level was significantly higher in NR compared to R for CDED&#x02009;+&#x02009;PEN (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02) and EEN (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.04). ROC analysis highlighted the robust predictive power of kynurenine for CDED&#x02009;+&#x02009;PEN (area under the curve (AUC&#x02009;=&#x02009;0.97)) and EEN (AUC&#x02009;=&#x02009;0.88)-induced remission. RFA corroborated these observations. The ratio serotonin/kynurenine was the strongest predictor of CDED&#x02009;+&#x02009;PEN-induced remission (AUC&#x02009;=&#x02009;1). The ratio 5-hydroxytryptophan/kynurenine (AUC&#x02009;=&#x02009;0.88) predicted EEN-induced remission. By combining data from CDED&#x02009;+&#x02009;PEN and EEN, kynurenine (AUC&#x02009;=&#x02009;0.91) and ratios of quinolinic acid/kynurenine (AUC&#x02009;=&#x02009;0.93) and kynurenine/indole-3-acetic acid (AUC&#x02009;=&#x02009;0.88) demonstrated strong predictive performance for dietary therapy-induced remission.</p></sec><sec id="section6-17562848251323004"><title>Conclusion:</title><p>Baseline tryptophan metabolites have the potential to serve as a biomarker for dietary remission in pediatric CD. Some tryptophan metabolite ratios showed the most promising predictive capabilities. If confirmed in validation studies, baseline fecal tryptophan markers may be able to provide much-needed guidance to personalize dietary intervention within the management of pediatric CD.</p></sec><sec id="section7-17562848251323004"><title>Trial registration:</title><p>NCT01728870.</p></sec></abstract><kwd-group><kwd>dietary therapy</kwd><kwd>feces</kwd><kwd>pediatric Crohn&#x02019;s disease</kwd><kwd>prediction of remission</kwd><kwd>tryptophan metabolites</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-17562848251323004"><funding-source id="funding1-17562848251323004">
<institution-wrap><institution>The AGEM talent development grant</institution><institution-id/></institution-wrap>
</funding-source></award-group><award-group id="award2-17562848251323004"><funding-source id="funding2-17562848251323004">
<institution-wrap><institution>Wetenschappelijke Advies Raad of Stichting Steun Emma</institution><institution-id/></institution-wrap>
</funding-source></award-group><award-group id="award3-17562848251323004"><funding-source id="funding3-17562848251323004">
<institution-wrap><institution>European Crohn's and Colitis Organisation</institution><institution-id/></institution-wrap>
</funding-source></award-group><award-group id="award4-17562848251323004"><funding-source id="funding4-17562848251323004">
<institution-wrap><institution>a Pro-KIIDS Clinical Research Network Award</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100018353</institution-id></institution-wrap>
</funding-source></award-group><award-group id="award5-17562848251323004"><funding-source id="funding5-17562848251323004">
<institution-wrap><institution>Nestle Health Science</institution><institution-id/></institution-wrap>
</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2025</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section8-17562848251323004"><title>Introduction</title><p>The increasing incidence of pediatric Crohn&#x02019;s disease (CD), a type of inflammatory bowel disease (IBD), has been strongly associated with a shift toward the Westernized diet.<sup><xref rid="bibr1-17562848251323004" ref-type="bibr">1</xref><xref rid="bibr2-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr3-17562848251323004" ref-type="bibr">3</xref></sup> While the etiology of CD remains largely unclear, multifactorial, and mostly complex polygenic, multiple studies have underscored the pivotal role of the gut microbiome and its interplay with dietary factors in the disease&#x02019;s pathogenesis.<sup><xref rid="bibr4-17562848251323004" ref-type="bibr">4</xref>,<xref rid="bibr5-17562848251323004" ref-type="bibr">5</xref></sup></p><p>The Westernized diet, characterized by a high intake of processed foods, refined sugars, saturated fats, and additives, has been linked to increased inflammation, altered gut microbial communities, and metabolic profiles including tryptophan.<sup><xref rid="bibr6-17562848251323004" ref-type="bibr">6</xref><xref rid="bibr7-17562848251323004" ref-type="bibr"/><xref rid="bibr8-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr9-17562848251323004" ref-type="bibr">9</xref></sup> Together, these lifestyle factors have been shown to contribute to both the onset and progression of CD.<sup><xref rid="bibr10-17562848251323004" ref-type="bibr">10</xref><xref rid="bibr11-17562848251323004" ref-type="bibr"/><xref rid="bibr12-17562848251323004" ref-type="bibr"/><xref rid="bibr13-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr14-17562848251323004" ref-type="bibr">14</xref></sup> Although dietary guidance is identified as a key priority by patients and patient organizations, it is often not offered as part of standard IBD management.<sup><xref rid="bibr15-17562848251323004" ref-type="bibr">15</xref><xref rid="bibr16-17562848251323004" ref-type="bibr"/><xref rid="bibr17-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr18-17562848251323004" ref-type="bibr">18</xref></sup></p><p>Several recent ECCO, ECCO/ESPGHAN, and ESPEN guidelines and reports have raised the profile of dietary therapy, for mild-to-moderate disease or as add-on therapy, for example, when additional immune suppression is undesirable.<sup><xref rid="bibr9-17562848251323004" ref-type="bibr">9</xref>,<xref rid="bibr19-17562848251323004" ref-type="bibr">19</xref><xref rid="bibr20-17562848251323004" ref-type="bibr"/><xref rid="bibr21-17562848251323004" ref-type="bibr"/><xref rid="bibr22-17562848251323004" ref-type="bibr"/><xref rid="bibr23-17562848251323004" ref-type="bibr"/><xref rid="bibr24-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr25-17562848251323004" ref-type="bibr">25</xref></sup> Meta-analyses have confirmed the superiority of nutritional therapy over corticosteroids for induction of clinical remission and mucosal healing using exclusive enteral nutrition (EEN), as well as better postoperative outcomes when used pre-operatively.<sup><xref rid="bibr26-17562848251323004" ref-type="bibr">26</xref><xref rid="bibr27-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr28-17562848251323004" ref-type="bibr">28</xref></sup></p><p>The Crohn&#x02019;s disease exclusion diet (CDED) combined with partial enteral nutrition (PEN) as well as EEN are both effective at inducing remission in mild-to-moderate CD but CDED&#x02009;+&#x02009;PEN is better tolerated.<sup><xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref><xref rid="bibr30-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr31-17562848251323004" ref-type="bibr">31</xref></sup> Both dietary options aim to reduce inflammatory dietary triggers while providing essential nutrients, but for most patients, the anti-inflammatory effect is quickly lost when normal diet is resumed.<sup><xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>,<xref rid="bibr30-17562848251323004" ref-type="bibr">30</xref>,<xref rid="bibr32-17562848251323004" ref-type="bibr">32</xref>,<xref rid="bibr33-17562848251323004" ref-type="bibr">33</xref></sup> While both dietary therapies have shown great effectiveness in inducing remission and improving clinical outcomes, adherence can be challenging. In addition, one-third of patients do not respond to dietary therapy.<sup><xref rid="bibr30-17562848251323004" ref-type="bibr">30</xref>,<xref rid="bibr31-17562848251323004" ref-type="bibr">31</xref>,<xref rid="bibr34-17562848251323004" ref-type="bibr">34</xref>,<xref rid="bibr35-17562848251323004" ref-type="bibr">35</xref></sup></p><p>Tryptophan, an essential amino acid primarily derived from dietary intake, plays a central role in several physiological functions.<sup>
<xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>
</sup> Tryptophan is a precursor for the synthesis of various bioactive molecules, including serotonin, indoles, kynurenine, and serotonin metabolism pathway components.<sup>
<xref rid="bibr37-17562848251323004" ref-type="bibr">37</xref>
</sup> Recent studies have emphasized the importance of tryptophan metabolic pathways in modulating intestinal immunity and maintaining gut homeostasis through activation of the AhR.<sup><xref rid="bibr38-17562848251323004" ref-type="bibr">38</xref><xref rid="bibr39-17562848251323004" ref-type="bibr"/><xref rid="bibr40-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr41-17562848251323004" ref-type="bibr">41</xref></sup></p><p>In the intestine, tryptophan is metabolized along three main routes, leading to kynurenine, serotonin, and indole derivative synthesis, under the direct or indirect involvement of the microbiota.<sup><xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>,<xref rid="bibr43-17562848251323004" ref-type="bibr">43</xref></sup> Alterations in gut microbiome composition, associated with CD, can consequently affect tryptophan.<sup><xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>,<xref rid="bibr43-17562848251323004" ref-type="bibr">43</xref>,<xref rid="bibr44-17562848251323004" ref-type="bibr">44</xref></sup> Our group and others have shown the association of tryptophan metabolism with intestinal and systemic inflammation, both when measured in serum and in feces, as well as using two-sample Mendelian randomization of available genome-wide association studies datasets.<sup><xref rid="bibr39-17562848251323004" ref-type="bibr">39</xref>,<xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>,<xref rid="bibr45-17562848251323004" ref-type="bibr">45</xref>,<xref rid="bibr46-17562848251323004" ref-type="bibr">46</xref></sup> Harris et al.<sup>
<xref rid="bibr45-17562848251323004" ref-type="bibr">45</xref>
</sup> have recently described reduced serum tryptophan levels across the majority of chronic inflammatory diseases (as evident by an inverse relationship between tryptophan and C-reactive protein (CRP). It is likely that increases in the kynurenine-to-tryptophan ratio (kynurenine/tryptophan)<sup>
<xref rid="bibr45-17562848251323004" ref-type="bibr">45</xref>
</sup> reflect the tryptophan metabolic pathway in inflammation through the enzymatic activity of indoleamine 2,3-dioxygenase (IDO)/tryptophan 2,3-dioxygenase in myeloid reactive immune cells.</p><p>In turn, achieving clinical remission of CD alters tryptophan metabolism, both with immune suppression and dietary therapy.<sup><xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>,<xref rid="bibr47-17562848251323004" ref-type="bibr">47</xref></sup> Wolf et al.<sup>
<xref rid="bibr47-17562848251323004" ref-type="bibr">47</xref>
</sup> previously showed that the tryptophan-metabolizing enzyme IDO expression, which in turn affects T-cell proliferation and survival, is reduced by anti-TNF therapy. In a translational research report of the index CDED-Randomized Controlled Trial (RCT), we showed that the strong reduction in kynurenine level was associated with induced and sustained remission and explained the association with the kynurenine/tryptophan ratio.<sup>
<xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>
</sup> A subsequent expanded analysis of tryptophan-metabolites in the same cohort, demonstrated that changes in specific tryptophan metabolites performed well as biomarkers of nutritional therapy outcome.<sup>
<xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>
</sup> More specifically, a reduction in the kynurenine pathway activity and an increase in serotonin pathway activity was associated with successful induction of, as well as sustained, remission to both CDED&#x02009;+&#x02009;PEN and EEN.<sup>
<xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>
</sup></p><p>Adherence to any form of dietary therapy is the key requirement for remission which in turn can help ascertain the degree to which the presenting phenotype is &#x0201c;diet-responsive.&#x0201d;<sup><xref rid="bibr48-17562848251323004" ref-type="bibr">48</xref><xref rid="bibr49-17562848251323004" ref-type="bibr"/><xref rid="bibr50-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr51-17562848251323004" ref-type="bibr">51</xref></sup> Given the significant lifestyle changes required for successful dietary therapy, an early indicator of likely remission is needed to personalize early treatment.<sup>
<xref rid="bibr34-17562848251323004" ref-type="bibr">34</xref>
</sup></p><p>In this study, we aim to analyze the tryptophan metabolite profile at baseline (pre-therapy) and investigate its potential to predict remission at Week 6 using either CDED&#x02009;+&#x02009;PEN or EEN.</p></sec><sec sec-type="methods" id="section9-17562848251323004"><title>Methods</title><sec id="section10-17562848251323004"><title>Participants</title><p>Participants are from a previously conducted 12-week RCT.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> In brief, children (4&#x02013;18&#x02009;years) with mild to moderate luminal CD (Pediatric Crohn&#x02019;s Disease Activity Index, PCDAI &#x0003e;10 and &#x02a7d;40) and active inflammation within 36&#x02009;months of diagnosis were eligible. Exclusion criteria included recent steroid use, immunomodulator adjustments, biologics use, primary colonic disease with rectal involvement, or active perianal disease. Of the original 78 participants from the RCT,<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> this subanalysis focused on 26 participants for whom baseline fecal samples were available for tryptophan metabolite analysis. This subset was selected due to the availability of stored samples following prior studies on metagenomics, 16S microbiome profiling, and metabolomics.<sup><xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>,<xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>,<xref rid="bibr52-17562848251323004" ref-type="bibr">52</xref></sup></p></sec><sec id="section11-17562848251323004"><title>Study design</title><p>Twenty-one tryptophan metabolites were quantified in 26 fecal samples collected from 26 pediatric CD patients at baseline, before therapy initiation, during a previously conducted 12-week RCT employing two distinct nutritional therapies: CDED&#x02009;+&#x02009;PEN and EEN for inducing remission in mild-to-moderate pediatric CD conducted in Israel and Canada, with sampling at baseline and Week 6.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup></p><p>The first group was assigned to the CDED, with additional PEN (MODULEN IBD; Nestl&#x000e9; Health Science, Vevey, Switzerland) accounting for 50% of their calculated energy requirements for a duration of 6&#x02009;weeks. This was followed by a transition to a step-down diet involving an additional 25% of energy requirements from PEN until Week 12, as previously described.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> The second group exclusively followed 100% EEN for 6&#x02009;weeks, after which they gradually resumed a regular diet with 25% of their caloric intake coming from PEN, as detailed in prior reports.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> The primary outcome measure in the RCT focused on assessing the tolerability of the dietary therapy. Secondary endpoints of the study included intention-to-treat remission at Week 6, defined by a PCDAI score of PCDAI&#x02009;&#x02a7d;&#x02009;10, and corticosteroid-free intention-to-treat sustained remission at Week 12. The study received ethical approval from the local ethics boards at each participating site, and informed consent was obtained from all participants (NCT01728870).</p><p>The primary objective of this study was to investigate whether any of the fecal tryptophan metabolites at baseline showed predictive capacity for therapy outcome (Remission (R) and No-Remission (NR)) after 6&#x02009;weeks of dietary therapy. Thus, fecal samples that were analyzed in this study were collected before the initiation of dietary therapy (time&#x02009;=&#x02009;0).</p></sec><sec id="section12-17562848251323004"><title>Subjects</title><p>Pediatric CD patients were stratified at baseline into remission (R) and no remission (NR) groups for CDED&#x02009;+&#x02009;PEN and EEN therapy, based on achieving remission or non-remission, defined by a PCDAI score of &#x02a7d;10 or &#x0003e;10, respectively, at Week 6.</p><p>The distribution of CDED&#x02009;+&#x02009;PEN fecal samples at baseline was as follows (total: <italic toggle="yes">n</italic>&#x02009;=&#x02009;13): R (<italic toggle="yes">n</italic>&#x02009;=&#x02009;10) and NR (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). For EEN fecal samples at baseline, the distribution was (total: <italic toggle="yes">n</italic>&#x02009;=&#x02009;13): R (<italic toggle="yes">n</italic>&#x02009;=&#x02009;9) and NR (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4).</p><p>Baseline characteristics and phenotype of patients are presented in <xref rid="table1-17562848251323004" ref-type="table">Table 1</xref>. CONSORT Checklist and study flow diagram were previously published.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup></p><table-wrap position="float" id="table1-17562848251323004"><label>Table 1.</label><caption><p>Baseline characteristics of patients.</p></caption><alternatives><graphic xlink:href="10.1177_17562848251323004-table1" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Non-remission<break/>(patients at baseline who fail to achieve remission at week 6)<break/>(<italic toggle="yes">n</italic>&#x02009;=&#x02009;7)</th><th align="left" rowspan="1" colspan="1">Remission<break/>(patients at baseline who achieve remission at week 6)<break/>(<italic toggle="yes">n</italic>&#x02009;=&#x02009;19)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Dietary therapy (<italic toggle="yes">n</italic>)</td><td rowspan="1" colspan="1">CDED&#x02009;+&#x02009;PEN (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3)<break/>EEN (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4)</td><td rowspan="1" colspan="1">CDED&#x02009;+&#x02009;PEN (<italic toggle="yes">n</italic>&#x02009;=&#x02009;10)<break/>EEN (<italic toggle="yes">n</italic>&#x02009;=&#x02009;9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age, year (mean&#x02009;&#x000b1;&#x02009;SD)</td><td rowspan="1" colspan="1">15.20 (&#x000b1;1.47)</td><td rowspan="1" colspan="1">13.73 (&#x000b1;1.26)</td><td rowspan="1" colspan="1">0.25</td></tr><tr><td rowspan="1" colspan="1">Gender (males%)</td><td rowspan="1" colspan="1">3 (42.8)</td><td rowspan="1" colspan="1">14 (73.6)</td><td rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">PCDAI (median, IQR)</td><td rowspan="1" colspan="1">28.93 (10&#x02013;40)</td><td rowspan="1" colspan="1">26.32 (12.5&#x02013;37.5)</td><td rowspan="1" colspan="1">0.97</td></tr><tr><td rowspan="1" colspan="1">CRP, mg/L (median, IQR)</td><td rowspan="1" colspan="1">2.45 (0.5&#x02013;5.21)</td><td rowspan="1" colspan="1">3.12 (0.5&#x02013;7.5)</td><td rowspan="1" colspan="1">0.58</td></tr><tr><td rowspan="1" colspan="1">Immunomodulators, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">2 (28.5)</td><td rowspan="1" colspan="1">2 (10.5)</td><td rowspan="1" colspan="1">0.27</td></tr><tr><td colspan="3" rowspan="1">Disease location Paris classification, <italic toggle="yes">n</italic></td><td rowspan="1" colspan="1">0.98</td></tr><tr><td rowspan="1" colspan="1">&#x02003;L1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;L2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;L3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;L4</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;L4a</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;L4b</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;L4a&#x02009;+&#x02009;b</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Not L4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-17562848251323004"><p>Source: Adapted from Levine et al.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup></p></fn><fn id="table-fn2-17562848251323004"><p>CDED, Crohn&#x02019;s disease exclusion diet; CRP, C-reactive protein; EEN, exclusive enteral nutrition; IQR, interquartile range; PCDAI, Pediatric Crohn&#x02019;s Disease Activity Index; PEN, partial enteral nutrition.</p></fn></table-wrap-foot></table-wrap><p>Each patient was supplied with two containers, which were labeled with stickers for easy identification. Upon sample collection (within a 24-h window), the container holding calprotectin was stored at &#x02212;20&#x000b0;C, while the microbiome/metabolome container was divided into four transfer tubes (Eppendorf tubes with black caps) using a wooden stick. These tubes were immediately stored at &#x02212;80&#x000b0;C, without the addition of any buffer.</p></sec><sec id="section13-17562848251323004"><title>Fecal tryptophan metabolites quantification</title><p>A targeted quantitative assessment of tryptophan metabolites in baseline fecal samples was conducted using liquid chromatography coupled with quadrupole mass spectrometry, as previously described.<sup><xref rid="bibr53-17562848251323004" ref-type="bibr">53</xref>,<xref rid="bibr54-17562848251323004" ref-type="bibr">54</xref></sup></p><p>To measure fecal tryptophan metabolites, we initiated the process by combining 3&#x02009;mg of lyophilized stool samples with 900&#x02009;&#x003bc;L of a MeOH/H<sub>2</sub>O mixture (1:1) alongside internal standards. Subsequently, these samples were subjected to vortexing, homogenization, and centrifugation. Following this, 100&#x02009;&#x000b5;L of the supernatants were carefully transferred to a 96-well plate for quantification of the metabolites, while the remaining 800&#x02009;&#x000b5;L were subjected to evaporation to dryness utilizing a vacuum concentrator (Savant SPD 111 vs SpeedVac; Thermo Fisher Scientific, Waltham, USA) at 45&#x000b0;C over a period of 4&#x02009;h. The resulting residues were then reconstituted in 100&#x02009;&#x003bc;L of MeOH/H<sub>2</sub>O mixture (1:9), with 2&#x02009;&#x000b5;L of the reconstituted solution being analyzed.</p><p>For the quantification via liquid chromatography-tandem mass spectrometry, we followed the previously established method.<sup>
<xref rid="bibr53-17562848251323004" ref-type="bibr">53</xref>
</sup> Calibration curves for each metabolite were established by calculating the intensity ratio between the metabolite and its corresponding internal standard. These calibration curves were subsequently employed to determine the concentrations of individual metabolites in the fecal samples. Detailed information regarding the specific calibration ranges and concentrations of internal standards, including the associated fragmentation parameters are described in Ghiboub et al.<sup>
<xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>
</sup></p><p>The set of 21 measured tryptophan metabolites encompassed a range of compounds, including tryptophan itself, metabolites from the kynurenine pathway (such as kynurenine, kynurenic acid, anthranilic acid, 3-OH-kynurenine, 3-OH-anthranilic acid, picolinic acid, and quinolinic acid), serotonin pathway metabolites (such as 5-OH-tryptophan, serotonin, N-acetylserotonin, melatonin, and 5-OH-indoleacetic acid), and indole pathway metabolites (including tryptamine, indoxyl sulfate (indole-3-sulfate), indole-3-acetamide, indole-3-acetic acid, indole-3-lactic acid, indole-3-aldehyde, tryptophol, and indole). <xref rid="fig1-17562848251323004" ref-type="fig">Figure 1</xref> provides a visual representation of the experimental setup and the positions of these measured metabolites within the various tryptophan metabolic pathways. The selection of these specific tryptophan metabolites was based on prior reports of their altered concentrations in various inflammatory diseases, including IBD.<sup><xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>,<xref rid="bibr38-17562848251323004" ref-type="bibr">38</xref>,<xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>,<xref rid="bibr43-17562848251323004" ref-type="bibr">43</xref></sup></p><fig position="float" id="fig1-17562848251323004"><label>Figure 1.</label><caption><p>Study design depicting remission and non-remission, with fecal sample sizes at baseline. <italic toggle="yes">n</italic>&#x02009;=&#x02009;13 for patients on EEN and <italic toggle="yes">n</italic>&#x02009;=&#x02009;13 for patients on CDED with PEN (CDED&#x02009;+&#x02009;PEN). Fecal samples at baseline (Week 0) were collected from patients subsequently categorized as responders and non-responders based on their clinical outcome of remission or non-remission at Week 6. Remission was defined as a PCDAI score &#x02a7d;10. The fecal samples were subjected to targeted quantitative analysis of 21 tryptophan metabolites. The schematic representation illustrates the positions of all measured metabolites in various tryptophan metabolism pathways.</p><p>Source: This diagram is updated from Levine et al.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> and Ghiboub et al.<sup>
<xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>
</sup></p><p>CDED, Crohn&#x02019;s disease exclusion diet; EEN, exclusive enteral nutrition; PCDAI, Pediatric Crohn&#x02019;s Disease Activity Index; PEN, partial enteral nutrition.</p></caption><graphic xlink:href="10.1177_17562848251323004-fig1" position="float"/></fig></sec><sec id="section14-17562848251323004"><title>Data processing and statistical analysis</title><p>Data preparation and subsequent statistical analyses were carried out using MetaboAnalyst 5.0, a widely recognized software web platform for metabolomics studies (<ext-link xlink:href="https://www.metaboanalyst.ca" ext-link-type="uri">https://www.metaboanalyst.ca</ext-link>).<sup>
<xref rid="bibr55-17562848251323004" ref-type="bibr">55</xref>
</sup></p><p>To enhance data quality, we employed the interquartile range method for data filtration, effectively identifying and removing variables that were deemed noisy or noninformative for subsequent modeling of the dataset, following established practices.<sup>
<xref rid="bibr56-17562848251323004" ref-type="bibr">56</xref>
</sup></p><p>Tryptophan metabolites were compared in three ways. We analyzed the combined data of remission (R) versus no remission (NR) for both therapies (CDED&#x02009;+&#x02009;PEN combined with EEN), as well as R versus NR specifically within the CDED&#x02009;+&#x02009;PEN and EEN groups. These comparisons allowed us to investigate potential prediction markers for dietary therapy in general, as well as for each specific dietary intervention. Receiver-operating characteristic (ROC) analysis was also conducted using MetaboAnalyst 5.0 (Xia lab, Montreal, Canada), a method previously outlined.<sup>
<xref rid="bibr57-17562848251323004" ref-type="bibr">57</xref>
</sup> This analysis utilized the normalized concentrations of 20 specific tryptophan metabolites. The key output measure of this analysis, the area under the ROC curve (AUC), was determined and accompanied by its corresponding 95% confidence intervals. Additionally, we instructed MetaboAnalyst 5.0 to compute and include all possible ratios among the top 20 pairs of tryptophan metabolites, based on their statistical significance (<italic toggle="yes">p</italic>-values). These ratios were subsequently incorporated into further biomarker analysis. From this comprehensive analysis, individual metabolites and metabolite ratios that exhibited an AUC of &#x02a7e;0.80 and a statistical significance level of <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 were singled out for further consideration. Random forest analysis (RFA) to normalized gut metabolite concentration levels with mean decrease accuracy was performed in MetaboAnalyst 5.0.<sup>
<xref rid="bibr55-17562848251323004" ref-type="bibr">55</xref>
</sup></p><p>The figures were adapted using Inkscape 0.92.4. For group-level analysis, the data underwent either one-way analysis of variance or Student&#x02019;s <italic toggle="yes">t</italic> test, with a significance threshold set at <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05. The data are depicted as the mean&#x02009;&#x000b1;&#x02009;standard error of the mean, adhering to standard statistical reporting practices.</p><p>The reporting of this study conforms to the STARD statement.<sup>
<xref rid="bibr58-17562848251323004" ref-type="bibr">58</xref>
</sup></p></sec></sec><sec sec-type="results" id="section15-17562848251323004"><title>Results</title><sec id="section16-17562848251323004"><title>Baseline characteristics of patients and rate of remission per group</title><p>CDED&#x02009;+&#x02009;PEN induced remission (defined as PCDAI &#x02a7d;10) in 10 (77%) out of 13 patients at Week 6 (<xref rid="fig1-17562848251323004" ref-type="fig">Figure 1</xref> and <xref rid="table1-17562848251323004" ref-type="table">Table 1</xref>). In the EEN group, of 13 patients, 9 (69%) achieved remission at Week 6 (<xref rid="fig1-17562848251323004" ref-type="fig">Figure 1</xref> and <xref rid="table1-17562848251323004" ref-type="table">Table 1</xref>). These numbers reflect only the patients with available fecal samples at baseline from the previously performed RCT.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> Similar to the RCT, analysis of this subgroup of patients revealed no significant differences in baseline characteristics (including PCDAI scores) in our subset of patients (<xref rid="table1-17562848251323004" ref-type="table">Table 1</xref>), illustrating that the groups were well-balanced.</p></sec><sec id="section17-17562848251323004"><title>Tryptophan metabolite concentrations as predictive biomarkers for non-remission to dietary intervention</title><p>We analyzed potential differences in baseline fecal tryptophan metabolite concentrations between patients starting dietary therapy (combining data from both CDED&#x02009;+&#x02009;PEN and EEN groups). Of the 21 tryptophan metabolites included in the analysis, 2 exhibited significant changes (<italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05; <xref rid="fig2-17562848251323004" ref-type="fig">Figure 2(a)</xref>). Baseline kynurenine level was more abundant in patients not achieving remission (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.009), while indole-3-acetic acid was less abundant (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.04; <xref rid="fig2-17562848251323004" ref-type="fig">Figure 2(a)</xref> and (<xref rid="fig2-17562848251323004" ref-type="fig">b</xref>)).</p><fig position="float" id="fig2-17562848251323004"><label>Figure 2.</label><caption><p>Elevated baseline fecal kynurenine and indole-3-acetic acid as predictive biomarkers for non-remission with dietary interventions (combined EEN and CDED&#x02009;+&#x02009;PEN data) in pediatric Crohn&#x02019;s disease. This figure presents a combined analysis of 21 baseline fecal tryptophan metabolites, pooling data from baseline fecal samples of both EEN and CDED with PEN (CDED&#x02009;+&#x02009;PEN) therapies. The aim is to identify potential differences in fecal tryptophan metabolites at baseline that may serve as predictive biomarkers for clinical outcomes at Week 6 of dietary therapy, comparing patients who achieved R with those who did not (NR). (a) Volcano plot illustrates the differences in fecal tryptophan metabolites between the combined R and combined NR groups. Blue dots indicate significantly decreased metabolites in combined R compared to combined NR, as determined by a <italic toggle="yes">t</italic> test (<italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05). Red dots represent significantly increased metabolites, while black dots denote metabolites with no significant changes. (b) Absolute concentrations of significantly altered fecal tryptophan metabolites, specifically kynurenine and indole-3-acetic acid, comparing data from R (<italic toggle="yes">n</italic>&#x02009;=&#x02009;19) and NR (<italic toggle="yes">n</italic>&#x02009;=&#x02009;7) groups. Data were analyzed using a Student&#x02019;s <italic toggle="yes">t</italic> test with a two-tailed significance level set at <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05.</p><p>CDED, Crohn&#x02019;s disease exclusion diet; EEN, exclusive enteral nutrition; NR, no-remission; PCDAI, Pediatric Crohn&#x02019;s Disease Activity Index; PEN, partial enteral nutrition; R, remission.</p></caption><graphic xlink:href="10.1177_17562848251323004-fig2" position="float"/></fig></sec><sec id="section18-17562848251323004"><title>Tryptophan metabolite concentrations as predictive biomarkers for non-remission to EEN or CDED&#x02009;+&#x02009;PEN</title><p>To identify potential differential tryptophan metabolites abundance as predictive biomarkers specific to each type of dietary therapy, we analyzed differences in baseline fecal tryptophan metabolite concentrations between patients who would go on to achieve remission through EEN or CDED&#x02009;+&#x02009;PEN separately and those who would not. Of the 21 baseline fecal tryptophan metabolites included in the analysis, one metabolite exhibited significant changes in the EEN cohort and 2 in the CDED&#x02009;+&#x02009;PEN cohort (<italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05; <xref rid="fig3-17562848251323004" ref-type="fig">Figure 3(a)&#x02013;(d)</xref>). Kynurenine was significantly more abundant in fecal samples from NR patients in both EEN (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.04) and CDED&#x02009;+&#x02009;PEN (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02; <xref rid="fig3-17562848251323004" ref-type="fig">Figure 3(b)</xref> and (<xref rid="fig3-17562848251323004" ref-type="fig">d</xref>)), while tryptophan was only significantly increased in NR fecal samples from patients on CDED&#x02009;+&#x02009;PEN (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.006; <xref rid="fig3-17562848251323004" ref-type="fig">Figure 3(a)</xref> and (<xref rid="fig3-17562848251323004" ref-type="fig">c</xref>)).</p><fig position="float" id="fig3-17562848251323004"><label>Figure 3.</label><caption><p>Therapy-dependent alterations in baseline fecal tryptophan metabolites predict R in pediatric Crohn&#x02019;s disease. This figure presents separate analyses of 21 baseline fecal tryptophan metabolites for EEN and CDED with PEN (CDED&#x02009;+&#x02009;PEN) therapies. The aim is to identify potential differential fecal tryptophan metabolite abundances at baseline that may serve as predictive biomarkers for clinical outcomes at Week 6, specific for each dietary therapy, comparing patients who would go on to achieved R with those who would not (NR). (a) Volcano plot illustrating differences in fecal tryptophan metabolites between R and NR groups for EEN therapy. Blue dots represent significantly decreased metabolites in R fecal samples compared to NR samples (<italic toggle="yes">t</italic> test, <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05). Black dots indicate metabolites with no significant changes. (b) Absolute concentrations of the significantly altered fecal tryptophan metabolite (kynurenine) in the EEN cohort, comparing R (<italic toggle="yes">n</italic>&#x02009;=&#x02009;9) with NR (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4). (c) Volcano plot showing differences in fecal tryptophan metabolites between R and NR groups for CDED&#x02009;+&#x02009;PEN therapy. Blue dots represent significantly decreased metabolites in R fecal samples compared to NR samples (<italic toggle="yes">t</italic> test, <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05). Black dots indicate metabolites with no significant changes. (d) Absolute concentrations of significantly altered fecal tryptophan metabolites in the CDED&#x02009;+&#x02009;PEN cohort, comparing R (<italic toggle="yes">n</italic>&#x02009;=&#x02009;10) with NR (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Data were analyzed using Student&#x02019;s <italic toggle="yes">t</italic> test with a two-tailed significance level set at <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05.</p><p>CDED, Crohn&#x02019;s disease exclusion diet; EEN, exclusive enteral nutrition; NR, no-remission; PEN, partial enteral nutrition; R, remission.</p></caption><graphic xlink:href="10.1177_17562848251323004-fig3" position="float"/></fig></sec><sec id="section19-17562848251323004"><title>Fecal kynurenine displays high prediction signature power for non-remission</title><p>ROC analysis showed kynurenine as the only tryptophan metabolite with a strong discriminatory power to predict the NR when CDED&#x02009;+&#x02009;PEN and EEN data are combined or for EEN alone (AUC&#x02009;=&#x02009;0.91, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001 and AUC&#x02009;=&#x02009;0.91, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02, respectively; <xref rid="fig4-17562848251323004" ref-type="fig">Figure 4(a)</xref> and (<xref rid="fig4-17562848251323004" ref-type="fig">b</xref>)). For CDED&#x02009;+&#x02009;PEN, kynurenine was the second strongest predictive biomarker with AUC&#x02009;=&#x02009;0.96 and <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02, after tryptophan with AUC&#x02009;=&#x02009;1 and <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01 (<xref rid="fig4-17562848251323004" ref-type="fig">Figure 4(c)</xref> and (<xref rid="fig4-17562848251323004" ref-type="fig">d</xref>)). Kynurenine was also one of the most important metabolites as a predictor in the RFA, corroborating the data generated from ROC analysis (<xref rid="fig4-17562848251323004" ref-type="fig">Figure 4(e)</xref>).</p><fig position="float" id="fig4-17562848251323004"><label>Figure 4.</label><caption><p>Kynurenine demonstrates high predictive power for NR with both EEN and CDED&#x02009;+&#x02009;PEN therapies. This figure presents prediction models applied to investigate the predictive power of individual fecal tryptophan metabolites at baseline to determine which patients would achieve remission at Week 6. (a&#x02013;d) ROC curves with corresponding AUC scores for fecal kynurenine in (a) combined CDED&#x02009;+&#x02009;PEN and EEN data (R: <italic toggle="yes">n</italic>&#x02009;=&#x02009;19, NR: <italic toggle="yes">n</italic>&#x02009;=&#x02009;7), (b) EEN alone (R: <italic toggle="yes">n</italic>&#x02009;=&#x02009;9, NR: <italic toggle="yes">n</italic>&#x02009;=&#x02009;4), (c) CDED&#x02009;+&#x02009;PEN alone (R: <italic toggle="yes">n</italic>&#x02009;=&#x02009;10, NR: <italic toggle="yes">n</italic>&#x02009;=&#x02009;3), and (d) tryptophan in CDED&#x02009;+&#x02009;PEN alone. Box plots illustrate raw values with associated <italic toggle="yes">p</italic>-values. This analysis compares patients who would achieve R with those who would not (NR). (e) Random forest analysis of normalized fecal tryptophan metabolite concentration levels. The top 5 metabolites with the highest discriminatory power between R and NR are shown for combined CDED&#x02009;+&#x02009;PEN and EEN data, EEN alone, and CDED&#x02009;+&#x02009;PEN alone. Red fields indicate high abundance (concentration), and blue fields indicate low abundance of the particular metabolite based on conditions.</p><p>AUC, area under the ROC curve; CDED, Crohn&#x02019;s disease exclusion diet; EEN, exclusive enteral nutrition; NR, no-remission; PEN, partial enteral nutrition; R, remission; ROC, receiver operating characteristic.</p></caption><graphic xlink:href="10.1177_17562848251323004-fig4" position="float"/></fig></sec><sec id="section20-17562848251323004"><title>Tryptophan metabolite ratios as a potential biomarker to predict non-remission</title><p>Metabolism is a dynamic process where catabolism and anabolism occur continuously, thus ratios between metabolites within the same human subject may yield better biomarkers and provide better overview about the specific pathway metabolism activity. Therefore, we opted to perform ROC analysis computed on metabolite ratios (pairwise). By applying the cut-off of AUC&#x02009;&#x0003e;&#x02009;0.8 and <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05, we detected 9, 6, and 9 tryptophan metabolite ratios as prediction signatures for clinical outcome of the combined data of CDED&#x02009;+&#x02009;PEN and EEN, EEN alone, and CDED&#x02009;+&#x02009;PEN alone, respectively (<xref rid="fig5-17562848251323004" ref-type="fig">Figure 5</xref>).</p><fig position="float" id="fig5-17562848251323004"><label>Figure 5.</label><caption><p>Tryptophan metabolite ratios as potential biomarkers for predicting remission in dietary interventions for pediatric Crohn&#x02019;s disease. This figure presents ROC analyses of fecal tryptophan metabolite ratios to evaluate their predictive power for remission at Week 6 following dietary interventions. This analysis compares fecal samples from patients who achieved R versus those who did not (NR). (a, c, and e) ROC curves with corresponding AUC scores for the most significant metabolite ratios (highest AUC score) in (a) combined EEN and CDED&#x02009;+&#x02009;PEN data (R: <italic toggle="yes">n</italic>&#x02009;=&#x02009;19, NR: <italic toggle="yes">n</italic>&#x02009;=&#x02009;7), (c) EEN alone (R: <italic toggle="yes">n</italic>&#x02009;=&#x02009;9, NR: <italic toggle="yes">n</italic>&#x02009;=&#x02009;4), and (e) CDED&#x02009;+&#x02009;PEN alone (R: <italic toggle="yes">n</italic>&#x02009;=&#x02009;10, NR: <italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Box plots display raw values with associated <italic toggle="yes">p</italic>-values. (b, d, and f) Summary tables of the most predictive signatures based on ROC analysis for individual metabolites and metabolite ratios. Ratios with AUC&#x02009;&#x0003e;&#x02009;0.8 and <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05 were considered significant for (b) combined EEN and CDED&#x02009;+&#x02009;PEN data, (d) EEN alone, and (f) CDED&#x02009;+&#x02009;PEN alone. In the tables, negative Log2 FC values indicate lower ratios in NR compared to R, while positive values indicate higher ratios in NR compared to R.</p><p>AUC, area under the curve; CDED, Crohn&#x02019;s disease exclusion diet; EEN, exclusive enteral nutrition; FC, fold change; NR, no-remission; PEN, partial enteral nutrition; R, remission; ROC, receiver operating characteristic.</p></caption><graphic xlink:href="10.1177_17562848251323004-fig5" position="float"/></fig><p>In general, the ratio of quinolinic acid-to-kynurenine displayed the most promising prediction signature of remission when combining the data of CDED&#x02009;+&#x02009;PEN and EEN or EEN alone, with AUC&#x02009;=&#x02009;0.93, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002 and AUC&#x02009;=&#x02009;1, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02, respectively (<xref rid="fig5-17562848251323004" ref-type="fig">Figure 5(a)&#x02013;(d)</xref>). While the ratio of serotonin-to-kynurenine (AUC&#x02009;=&#x02009;1 and <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.006; <xref rid="fig5-17562848251323004" ref-type="fig">Figure 5(e)</xref> and (<xref rid="fig5-17562848251323004" ref-type="fig">f</xref>)) was ranked as the best predictor for CDED&#x02009;+&#x02009;PEN therapy remission, quinolinic acid-to-kynurenine also displayed a high prediction power with AUC&#x02009;=&#x02009;0.9 (<xref rid="fig5-17562848251323004" ref-type="fig">Figure 5(f)</xref>). It is worth mentioning that the ratio of kynurenine-to-indole-3-acetic acid displayed high prediction power for both nutritional therapies, as well as when we combined their data, with AUC&#x02009;&#x0003e;&#x02009;0.8 and <italic toggle="yes">p</italic>&#x02009;&#x02a7d;&#x02009;0.05. Some other interesting ratio signatures are also listed in <xref rid="fig5-17562848251323004" ref-type="fig">Figure 5(b)</xref>, (<xref rid="fig5-17562848251323004" ref-type="fig">d</xref>), and (<xref rid="fig5-17562848251323004" ref-type="fig">f</xref>).</p></sec></sec><sec sec-type="discussion" id="section21-17562848251323004"><title>Discussion</title><p>In this study, we have shown that tryptophan metabolites, particularly kynurenine, may have potential as biomarkers of remission with nutritional therapy in children with de novo CD. Previously, we showed the association of kynurenine and the ratio of kynurenine/tryptophan with clinical remission at Week 6 and sustained remission at Week 12.<sup><xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>,<xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref></sup> Herein, we show that already baseline assessment of kynurenine and ratios of tryptophan metabolites, reflecting the various downstream pathways away from kynurenine, have the potential to predict dietary remission and non-remission 6&#x02009;weeks later.</p><p>For this study, we used available samples from the index RCT of CDED&#x02009;+&#x02009;PEN versus EEN which was a cohort of mostly treatment-na&#x000ef;ve teenagers with ileal involvement.<sup><xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>,<xref rid="bibr48-17562848251323004" ref-type="bibr">48</xref></sup> Previous analyses have focused on various metagenome, inferred metabolic phenotype, and unbiased metabolome analyses.<sup><xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>,<xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>,<xref rid="bibr52-17562848251323004" ref-type="bibr">52</xref></sup> We showed that the metabolic phenotype (metabotype) shifts toward healthy controls which each additional week of nutritional therapy.<sup>
<xref rid="bibr52-17562848251323004" ref-type="bibr">52</xref>
</sup> Fecal short chain fatty acids (SCFAs) and standard primary and secondary bile acids did not appear to be the main mechanisms of action of nutritional therapy. Instead, a wide range of other metabolic pathways including microbial amino acid metabolism were identified to play a role in achieving remission.<sup>
<xref rid="bibr36-17562848251323004" ref-type="bibr">36</xref>
</sup></p><p>Tryptophan metabolism has received increasing research attention in immune-mediated disease as it integrates environmental exposures including diet with inflammation in a variety of tissues, settings, and diseases. The microbiome-host interaction critical to the development and disease course in IBD influences the selective metabolism of tryptophan into the three established downstream pathways (Kynurenine, Serotonin (both host), and indole (microbial)).<sup><xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>,<xref rid="bibr59-17562848251323004" ref-type="bibr">59</xref></sup> Long-term dietary patterns have repeatedly been associated with CD susceptibility and microbiome features, associated with inflammation.<sup><xref rid="bibr14-17562848251323004" ref-type="bibr">14</xref>,<xref rid="bibr60-17562848251323004" ref-type="bibr">60</xref></sup> Recently, the Gene-Environment-Microbiome cohort study showed that microbiome changes predate the onset of inflammation in a cohort of siblings of patients with IBD, some of whom have gone on to develop IBD.<sup><xref rid="bibr61-17562848251323004" ref-type="bibr">61</xref>,<xref rid="bibr62-17562848251323004" ref-type="bibr">62</xref></sup> Modification of dietary exposure will therefore be receiving increasing research interest in the pre-clinical/at-risk phase before the onset of inflammation.<sup><xref rid="bibr63-17562848251323004" ref-type="bibr">63</xref><xref rid="bibr64-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr65-17562848251323004" ref-type="bibr">65</xref></sup></p><p>In our previous study,<sup>
<xref rid="bibr42-17562848251323004" ref-type="bibr">42</xref>
</sup> we observed that specific tryptophan metabolites, particularly those in the kynurenine pathway, such as increased levels of kynurenine and quinolinic acid, were strongly associated with non-remission to both EEN and CDED&#x02009;+&#x02009;PEN at Week 6. This finding suggests that achieving remission at Week 6 may require lower levels of these metabolites. Interestingly, our current study shows that patients who did not respond to dietary therapy at Week 6 already exhibited elevated levels of kynurenine at baseline (Week 0). This indicates that this metabolite could serve as a strong biomarker for predicting therapy outcomes, notably dietary therapy in CD. Additionally, this opens new research avenues, as this metabolite might contribute to the lack of response in some patients and could potentially be targeted to improve remission rates. The persistent elevation of these metabolites in non-responders highlights their possible role in the disease&#x02019;s pathophysiology and suggests that modulation of the kynurenine pathway could be a therapeutic target. Further research is warranted to explore causal relationships and to develop targeted interventions that may enhance remission rates by addressing these metabolic pathways.</p><p>In the early stages of CD therapy, the identification of a diet-responsive phenotype can inform decisions regarding the appropriate vaccination strategy versus the timely introduction of immunomodulators/anti-TNF.<sup><xref rid="bibr34-17562848251323004" ref-type="bibr">34</xref>,<xref rid="bibr66-17562848251323004" ref-type="bibr">66</xref></sup> Recently, the regulatory effect of nutritional therapy on inflammation has been described.<sup><xref rid="bibr67-17562848251323004" ref-type="bibr">67</xref><xref rid="bibr68-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr69-17562848251323004" ref-type="bibr">69</xref></sup> In keeping with this research, restricting a dietary intervention to 6&#x02009;weeks has repeatedly been shown to lead to undertreatment/early flare, particularly in the moderate-to-severe group of patients.<sup>
<xref rid="bibr68-17562848251323004" ref-type="bibr">68</xref>
</sup> In the landmark study by Jongsma et al.,<sup><xref rid="bibr68-17562848251323004" ref-type="bibr">68</xref>,<xref rid="bibr70-17562848251323004" ref-type="bibr">70</xref></sup> azathioprine was unable to control this rebound inflammation (replicating the larger experience with thiopurines in adult CD).<sup><xref rid="bibr19-17562848251323004" ref-type="bibr">19</xref>,<xref rid="bibr71-17562848251323004" ref-type="bibr">71</xref></sup> On the other hand, an indolent course of CD may benefit from and be sufficiently treated by controlling inflammatory triggers through dietary management.<sup><xref rid="bibr30-17562848251323004" ref-type="bibr">30</xref>,<xref rid="bibr72-17562848251323004" ref-type="bibr">72</xref></sup></p><p>In mild-to-moderate CD (B1 in the Montreal/Paris classification), many practitioners choose to avoid corticosteroid exposure, but the best type of nutritional intervention spanning induction and maintenance of remission is still the subject of debate.<sup><xref rid="bibr9-17562848251323004" ref-type="bibr">9</xref>,<xref rid="bibr15-17562848251323004" ref-type="bibr">15</xref>,<xref rid="bibr19-17562848251323004" ref-type="bibr">19</xref></sup> A reliable marker to give an early indication of the likelihood of dietary remission has been lacking. Nichols et al.<sup>
<xref rid="bibr73-17562848251323004" ref-type="bibr">73</xref>
</sup> have recently identified a range of microbial signals and diet-related metabolites in feces. Paradoxically, remission associated with EEN as well as the prediction of the likelihood of remission are linked to lower levels of SCFAs. In their study, as well as in the recent larger analysis of the Canadian pediatric IBD inception cohort, pre-existing diet may be a large confounder and determinant of baseline microbiome and remission with nutritional therapy.<sup>
<xref rid="bibr74-17562848251323004" ref-type="bibr">74</xref>
</sup> A better understanding of pre-diagnosis diet and baseline microbiome can avoid undertreatment due to incorrect guidance. In this regard, important lessons can be drawn from previous PEN&#x02019;s studies showing a significantly lower remission rate compared to EEN.<sup><xref rid="bibr4-17562848251323004" ref-type="bibr">4</xref>,<xref rid="bibr75-17562848251323004" ref-type="bibr">75</xref>,<xref rid="bibr76-17562848251323004" ref-type="bibr">76</xref></sup></p><p>Through the identification and exclusion of potential food-derived triggers of inflammation, far beyond the often selectively quoted reduction of emulsifiers, the CDED&#x02009;+&#x02009;PEN intervention has proven to be an important incremental change to the role of diet in induction and maintenance of remission extending beyond pediatric practice.<sup><xref rid="bibr19-17562848251323004" ref-type="bibr">19</xref>,<xref rid="bibr21-17562848251323004" ref-type="bibr">21</xref>,<xref rid="bibr32-17562848251323004" ref-type="bibr">32</xref></sup> Early identification of markers of the likelihood of successful induction of remission can help guide induction as well as potential for dietary maintenance.</p><p>In the search for predictive markers, it is important to discuss the characteristics of the cohort used to develop the biomarker.<sup>
<xref rid="bibr77-17562848251323004" ref-type="bibr">77</xref>
</sup> In the index RCT of CDED&#x02009;+&#x02009;PEN, all included patients had mild-to-moderate disease as defined by the PCDAI, were required to have ileal involvement, and not to have severe disease in the rectosigmoid.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> Indeed, some historical case series had suggested isolated colonic disease is less amenable to dietary treatment but lack of differentiation between right-sided colonic and distal colonic disease involvement, may be important to fully characterize the response of colonic-predominant disease.<sup><xref rid="bibr78-17562848251323004" ref-type="bibr">78</xref>,<xref rid="bibr79-17562848251323004" ref-type="bibr">79</xref></sup> In the cohort included in the CDED&#x02009;+&#x02009;PEN RCT, the Paris-location of disease was not a significant predictor of remission.<sup>
<xref rid="bibr48-17562848251323004" ref-type="bibr">48</xref>
</sup></p><p>Dhaliwal et al.<sup>
<xref rid="bibr80-17562848251323004" ref-type="bibr">80</xref>
</sup> have shown a poor correlation between PCDAI and markers of endoscopic severity in pediatric CD. Also in terms of prediction of disease course, it is pertinent to note that, for example, colonic ulceration is not uniformly associated with worse outcomes in more recent cohorts, treated with anti-TNF, whereas ileal ulceration is less likely to respond to anti-TNF.<sup><xref rid="bibr81-17562848251323004" ref-type="bibr">81</xref>,<xref rid="bibr82-17562848251323004" ref-type="bibr">82</xref></sup></p><p>Beyond disease location and behavior at diagnosis (e.g., penetrating disease, perianal disease), previous attempts to include complex biomarkers in personalizing CD therapy, have not been widely adopted in pediatric CD, for example, NOD2/CARD15 genetics, anti-microbial serology.<sup>
<xref rid="bibr83-17562848251323004" ref-type="bibr">83</xref>
</sup> According to the Beaugerie criteria, pediatric age at diagnosis alone is associated with worse disease course.<sup>
<xref rid="bibr84-17562848251323004" ref-type="bibr">84</xref>
</sup> Atia et al.<sup><xref rid="bibr85-17562848251323004" ref-type="bibr">85</xref><xref rid="bibr86-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr87-17562848251323004" ref-type="bibr">87</xref></sup> have illustrated the lack of reliable biomarkers of severity in pediatric CD with available rarely RCTs able to reflect the breadth of phenotypes of the patient population in CD. Ricciuto et al.<sup>
<xref rid="bibr88-17562848251323004" ref-type="bibr">88</xref>
</sup> have shown the relationship between complicated disease and growth impairment with diagnostic delay. In our cohort, most patients were included shortly after diagnosis.</p><p>In the absence of widely applicable clinical, genetic, or serological biomarkers, the failure of the 17-gene transcriptional biomarker in the PROFILE study of anti-TNF use is particularly noteworthy.<sup>
<xref rid="bibr89-17562848251323004" ref-type="bibr">89</xref>
</sup> Derived from a CD8 T-cell transcription profile associated with the progression of disease (evidenced by a need for immunomodulatory therapy or surgery), external validation prior to the use in the PROFILE study still did not lead to added benefit in the first biomarker-stratified trial design.<sup>
<xref rid="bibr90-17562848251323004" ref-type="bibr">90</xref>
</sup> When we consider the complex polygenic host&#x02013;microbiome interaction associated with disease development and disease course, as discussed above, markers such as tryptophan-metabolites (alone or in the future perhaps in combination with other metabotype measures), which inherently merge host genetics, immunology, and microbiome, may bridge this gap from host-focused biomarker development to an integrative disease marker. The findings in our much smaller cohort of nutritional therapy will obviously require validation in larger cohorts of similar disease phenotype and duration.</p><p>Further research into such markers may inform strategies to improve the therapeutic ceiling encountered for all drugs to date. Aden et al.<sup>
<xref rid="bibr91-17562848251323004" ref-type="bibr">91</xref>
</sup> have previously described that the long-term response to anti-TNF is associated with microbiome features at baseline (e.g., SCFA generating capability as a marker of a less dysbiotic state). Previous attempts to reduce lifestyle and dietary management to adding or removing a single food item have been scarce and mostly underwhelming.<sup><xref rid="bibr49-17562848251323004" ref-type="bibr">49</xref>,<xref rid="bibr50-17562848251323004" ref-type="bibr">50</xref>,<xref rid="bibr92-17562848251323004" ref-type="bibr">92</xref></sup> Recent data on the complexity of, for example, fiber supplementation, with its effect depending on the microbiome/inflammatory state of the intestine, are illustrative of the complexity required of dietary intervention, both in composition and in time.<sup>
<xref rid="bibr93-17562848251323004" ref-type="bibr">93</xref>
</sup> The potential of a baseline marker such as tryptophan metabolites, which does not require complex bioinformatics and is yet able to reflect the degree of dysbiosis sufficiently to predict the likelihood of diet-induced remission, is highly promising to prioritize for further studies. The link of tryptophan metabolism with several IBD-associated mechanisms through the Aryl hydrocarbon receptor (bridging microbiome, appropriate regulation of immunity warrants further translational studies given the complexity of AhR biology).<sup><xref rid="bibr94-17562848251323004" ref-type="bibr">94</xref><xref rid="bibr95-17562848251323004" ref-type="bibr"/><xref rid="bibr96-17562848251323004" ref-type="bibr"/><xref rid="bibr97-17562848251323004" ref-type="bibr"/>&#x02013;<xref rid="bibr98-17562848251323004" ref-type="bibr">98</xref></sup></p><p>The samples were from a previously conducted international RCT with a homogeneous and well-characterized cohort that included extensive multi-omics data. Limitations of our study include the small sample size, particularly the small number of patients not achieving remission. Previous analyses on a larger subgroup of this cohort (due to the greater availability of fecal samples at that time, before other multi-omics analyses were reported) triggered the in-depth analysis of tryptophan metabolism reported herein.</p><p>In this study, remission at Week 6 was determined solely based on the PDCAI score, in keeping with the outcomes used in the RCT. We have previously shown normalization of CRP for most children in this cohort with dietary therapy.<sup>
<xref rid="bibr29-17562848251323004" ref-type="bibr">29</xref>
</sup> Fecal calprotectin was markedly elevated in both groups ranging between 50 and 17,000&#x02009;&#x003bc;g/g at entry. Calprotectin dropped significantly for both groups between Week 0 and Week 6 (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17562848251323004" ext-link-type="uri">Supplemental Figure 1</ext-link>). There was no statistically significant difference in median delta calprotectin between CDED&#x02009;+&#x02009;PEN and EEN, which represents a 49.0% and 56% drop in median calprotectin, respectively, by Week 6 (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17562848251323004" ext-link-type="uri">Supplemental Figure 1</ext-link>). Future studies are suggested to have longer follow-ups and incorporate combined analyses based on PDCIA score, systemic inflammation (CRP), mucosal inflammation (calprotectin), and microbiome/metabolome signatures to provide more insights.</p><p>Since tryptophan pathways include numerous metabolites not covered in this study, this inevitably results in a lower resolution of the analysis of complex metabolic pathways. The use of ratios to highlight differences between groups increases the number of comparisons, raising the risk of overfitting and false discoveries, especially given our small sample size. While this approach is biologically plausible and aligns with previous studies, we acknowledge this limitation and emphasize that our findings are exploratory. Future research with larger cohorts and longer follow-ups is needed to validate these results.</p><p>In conclusion, we have provided evidence across different time points within a cohort from a previous RCT that tryptophan metabolites are associated with remission with dietary therapy. Additionally, we have demonstrated clear differences in kynurenine and tryptophan metabolite ratios at baseline that are associated with diet-induced remission at Week 6. We identified a potential biomarker that could help predict remission to dietary therapy, allowing for personalized treatment and preventing unnecessary dietary restrictions. Further studies are warranted to confirm these findings.</p></sec><sec sec-type="supplementary-material" id="section22-17562848251323004" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-17562848251323004" position="float" content-type="local-data"><caption><title>sj-jpg-1-tag-10.1177_17562848251323004 &#x02013; Supplemental material for Tryptophan metabolites profile predict remission with dietary therapy in pediatric Crohn&#x02019;s disease</title></caption><media xlink:href="sj-jpg-1-tag-10.1177_17562848251323004.jpg"/><p>Supplemental material, sj-jpg-1-tag-10.1177_17562848251323004 for Tryptophan metabolites profile predict remission with dietary therapy in pediatric Crohn&#x02019;s disease by Rotem Sigall Boneh, Nikki van der Kruk, Eytan Wine, Charlotte M. Verburgt, Tim G. J. de Meij, Mark L&#x0fffd;wenberg, Krisztina B. Gecse, Nicolette Wierdsma, Joep P. M. Derikx, Wouter J. de Jonge, Geert D&#x02019;Haens, Mohammed Ghiboub and Johan E. Van Limbergen in Therapeutic Advances in Gastroenterology</p></supplementary-material></sec></body><back><ack><p>We gratefully acknowledge the expertise and services of Dr Bruno Sovran (Tytgat Institute for Liver and Intestinal Research, Amsterdam), Antoine Lef&#x000e8;vre, and Prof. Patrick Emond from the University of Tours, France, for their valuable contribution to measuring tryptophan metabolites using liquid chromatography coupled with quadrupole mass spectrometry. The authors would like to thank all participating children and their families. The authors also thank Arie Levine for the design of the diet and his contribution to the study, as well as the many colleagues in pediatric gastroenterology and nutrition at all participating sites, who made this study possible: in Tel Aviv (Tamar Pfeffer-Gik who initially coordinated the study and Chen Sarbagili Shabat), Halifax (Anthony Otley, Mohsin Rashid, Angela Noble, Jessica Connors, Jennifer Haskett, Lisa Parkinson-McGraw, Brad MacIntyre), Edmonton (Hien Huynh, Matthew Carroll, Alexandra Petrova, Min Chen, Jessica Wu). Antonia Harvey, registered dietitian, and M. Whebby, research assistant, modified the CDED recipes for use in Canada and maintained the Canadian CDED study website, supervised by Shannan Grant, Department of Applied Human Nutrition, Mount Saint Vincent University.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Nicolette Wierdsma <inline-graphic xlink:href="10.1177_17562848251323004-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-0125-0680" ext-link-type="uri">https://orcid.org/0000-0002-0125-0680</ext-link></p><p>Mohammed Ghiboub <inline-graphic xlink:href="10.1177_17562848251323004-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-2095-371X" ext-link-type="uri">https://orcid.org/0000-0002-2095-371X</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><sec id="section23-17562848251323004"><title>Declarations</title><fn-group><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> The study is registered as NCT01728870. The study was approved by the local ethics board at each of the participating sites. Consent was obtained from each of the participants/family as appropriate.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Rotem Sigall Boneh:</bold> Formal analysis; Investigation; Visualization; Writing &#x02013; original draft; Writing &#x02013; review &#x00026; editing.</p><p><bold>Nikki van der Kruk:</bold> Formal analysis; Visualization; Writing &#x02013; original draft; Writing &#x02013; review &#x00026; editing.</p><p><bold>Eytan Wine:</bold> Investigation; Writing &#x02013; review &#x00026; editing.</p><p><bold>Charlotte M. Verburgt:</bold> Methodology; Writing &#x02013; review &#x00026; editing.</p><p><bold>Tim G. J. de Meij:</bold> Investigation; Writing &#x02013; review &#x00026; editing.</p><p><bold>Mark L&#x000f6;wenberg:</bold> Investigation; Writing &#x02013; review &#x00026; editing.</p><p><bold>Krisztina B. Gecse:</bold> Investigation; Writing &#x02013; review &#x00026; editing.</p><p><bold>Nicolette Wierdsma:</bold> Investigation; Writing &#x02013; review &#x00026; editing.</p><p><bold>Joep P. M. Derikx:</bold> Writing &#x02013; review &#x00026; editing.</p><p><bold>Wouter J. de Jonge:</bold> Investigation; Supervision; Writing &#x02013; review &#x00026; editing.</p><p><bold>Geert D&#x02019;Haens:</bold> Investigation; Writing &#x02013; review &#x00026; editing.</p><p><bold>Mohammed Ghiboub:</bold> Conceptualization; Formal analysis; Funding acquisition; Investigation; Supervision; Visualization; Writing &#x02013; original draft; Writing &#x02013; review &#x00026; editing.</p><p><bold>Johan E. Van Limbergen:</bold> Conceptualization; Data curation; Funding acquisition; Investigation; Methodology; Project administration; Supervision; Writing &#x02013; original draft; Writing &#x02013; review &#x00026; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: J.E.V.L. was supported by funding from the Amsterdam UMC; Wetenschappelijke Advies Raad of Stichting Steun Emma (Emma Children&#x02019;s Hospital); the Department of Pediatrics, Amsterdam University Medical Centers; a Pro-KIIDS Clinical Research Network Award (#585718) and a Life Sciences and Health Public Private Partnership of Health Holland and Nestle Health Science. J.E.V.L. received research funds from Nestle Health Science. J.E.V.L. received funds for consulting and speaking from Nestle Health Science, Pfizer, and Nutricia and for participation in advisory boards from Nestle Health Science and Pfizer. M.G. was supported by funding from European Crohn&#x02019;s and Colitis Organization Grant and The Amsterdam Gastroenterology Endocrinology Metabolism Talent Development Grant.</p></fn><fn fn-type="COI-statement"><p>The authors declare that there is no conflict of interest.</p></fn><fn fn-type="other"><p><bold>Availability of data and materials:</bold> Metagenome and metabolome data were previously made publicly available in Levine et al. 2019, Ghiboub et al. 2022, and Verburgt et al. 2023.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bibr1-17562848251323004"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kuenzig</surname><given-names>ME</given-names></name>
<name><surname>Fung</surname><given-names>SG</given-names></name>
<name><surname>Marderfeld</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review</article-title>. <source>Gastroenterology</source>
<year>2022</year>; <volume>162</volume>(<issue>4</issue>): 1147&#x02013;1159.e4.</mixed-citation></ref><ref id="bibr2-17562848251323004"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Coward</surname><given-names>S</given-names></name>
<name><surname>Clement</surname><given-names>F</given-names></name>
<name><surname>Benchimol</surname><given-names>EI</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Past and future burden of inflammatory bowel diseases based on modeling of population-based data</article-title>. <source>Gastroenterology</source>
<year>2019</year>; <volume>156</volume>(<issue>5</issue>): 1345&#x02013;1353.e4.</mixed-citation></ref><ref id="bibr3-17562848251323004"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>SE</given-names></name>
<name><surname>Thorne</surname><given-names>K</given-names></name>
<name><surname>Thapar</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>A systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe</article-title>. <source>J Crohns Colitis</source>
<year>2020</year>; <volume>14</volume>(<issue>8</issue>): <fpage>1119</fpage>&#x02013;<lpage>1148</lpage>.<pub-id pub-id-type="pmid">32115645</pub-id>
</mixed-citation></ref><ref id="bibr4-17562848251323004"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>JD</given-names></name>
<name><surname>Chen</surname><given-names>EZ</given-names></name>
<name><surname>Baldassano</surname><given-names>RN</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn&#x02019;s disease</article-title>. <source>Cell Host Microbe</source>
<year>2015</year>; <volume>18</volume>(<issue>4</issue>): <fpage>489</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">26468751</pub-id>
</mixed-citation></ref><ref id="bibr5-17562848251323004"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Z</given-names></name>
<name><surname>Liu</surname><given-names>R</given-names></name>
<name><surname>Gao</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries</article-title>. <source>Nat Genet</source>
<year>2023</year>; <volume>55</volume>(<issue>5</issue>): <fpage>796</fpage>&#x02013;<lpage>806</lpage>.<pub-id pub-id-type="pmid">37156999</pub-id>
</mixed-citation></ref><ref id="bibr6-17562848251323004"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sugino</surname><given-names>KY</given-names></name>
<name><surname>Janssen</surname><given-names>RC</given-names></name>
<name><surname>McMahan</surname><given-names>RH</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Vertical transfer of maternal gut microbes to offspring of western diet-fed dams drives reduced levels of tryptophan metabolites and postnatal innate immune response</article-title>. <source>Nutrients</source>
<year>2024</year>; <volume>16</volume>(<issue>12</issue>): <fpage>1808</fpage>.<pub-id pub-id-type="pmid">38931163</pub-id>
</mixed-citation></ref><ref id="bibr7-17562848251323004"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>P</given-names></name>
<name><surname>Wang</surname><given-names>M</given-names></name>
<name><surname>Liu</surname><given-names>YX</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>High-fat diet-disturbed gut microbiota-colonocyte interactions contribute to dysregulating peripheral tryptophan-kynurenine metabolism</article-title>. <source>Microbiome</source>
<year>2023</year>; <volume>11</volume>(<issue>1</issue>): <fpage>154</fpage>.<pub-id pub-id-type="pmid">37468922</pub-id>
</mixed-citation></ref><ref id="bibr8-17562848251323004"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fritsch</surname><given-names>J</given-names></name>
<name><surname>Garces</surname><given-names>L</given-names></name>
<name><surname>Quintero</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Low-fat, high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2021</year>; <volume>19</volume>(<issue>6</issue>): 1189&#x02013;1199.e30.</mixed-citation></ref><ref id="bibr9-17562848251323004"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hashash</surname><given-names>JG</given-names></name>
<name><surname>Elkins</surname><given-names>J</given-names></name>
<name><surname>Lewis</surname><given-names>JD</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>AGA clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review</article-title>. <source>Gastroenterology</source>
<year>2024</year>; <volume>166</volume>(<issue>3</issue>): <fpage>521</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">38276922</pub-id>
</mixed-citation></ref><ref id="bibr10-17562848251323004"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>CMA</given-names></name>
<name><surname>Connors</surname><given-names>J</given-names></name>
<name><surname>Dunn</surname><given-names>KA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Bacterial taxa and functions are predictive of sustained remission following exclusive enteral nutrition in pediatric Crohn&#x02019;s disease</article-title>. <source>Inflamm Bowel Dis</source>
<year>2020</year>; <volume>26</volume>(<issue>7</issue>): <fpage>1026</fpage>&#x02013;<lpage>1037</lpage>.<pub-id pub-id-type="pmid">31961432</pub-id>
</mixed-citation></ref><ref id="bibr11-17562848251323004"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Levine</surname><given-names>A</given-names></name>
<name><surname>Sigall Boneh</surname><given-names>R</given-names></name>
<name><surname>Wine</surname><given-names>E</given-names></name>
</person-group>. <article-title>Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases</article-title>. <source>Gut</source>
<year>2018</year>; <volume>67</volume>(<issue>9</issue>): <fpage>1726</fpage>&#x02013;<lpage>1738</lpage>.<pub-id pub-id-type="pmid">29777041</pub-id>
</mixed-citation></ref><ref id="bibr12-17562848251323004"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lo</surname><given-names>CH</given-names></name>
<name><surname>Lochhead</surname><given-names>P</given-names></name>
<name><surname>Khalili</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Dietary inflammatory potential and risk of Crohn&#x02019;s disease and ulcerative colitis</article-title>. <source>Gastroenterology</source>
<year>2020</year>; <volume>159</volume>(<issue>3</issue>): 873&#x02013;883.e1.</mixed-citation></ref><ref id="bibr13-17562848251323004"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Peters</surname><given-names>V</given-names></name>
<name><surname>Spooren</surname><given-names>C</given-names></name>
<name><surname>Pierik</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Dietary intake pattern is associated with occurrence of flares in IBD patients</article-title>. <source>J Crohns Colitis</source>
<year>2021</year>; <volume>15</volume>(<issue>8</issue>): <fpage>1305</fpage>&#x02013;<lpage>1315</lpage>.<pub-id pub-id-type="pmid">33439251</pub-id>
</mixed-citation></ref><ref id="bibr14-17562848251323004"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Peters</surname><given-names>V</given-names></name>
<name><surname>Bolte</surname><given-names>L</given-names></name>
<name><surname>Schuttert</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Western and carnivorous dietary patterns are associated with greater likelihood of IBD-development in a large prospective population-based cohort</article-title>. <source>J Crohns Colitis</source>
<year>2022</year>; <volume>16</volume>(<issue>6</issue>): <fpage>931</fpage>&#x02013;<lpage>939</lpage>.<pub-id pub-id-type="pmid">34864946</pub-id>
</mixed-citation></ref><ref id="bibr15-17562848251323004"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Levine</surname><given-names>A</given-names></name>
<name><surname>Rhodes</surname><given-names>JM</given-names></name>
<name><surname>Lindsay</surname><given-names>JO</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Dietary guidance from the international organization for the study of inflammatory bowel diseases</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2020</year>; <volume>18</volume>(<issue>6</issue>): <fpage>1381</fpage>&#x02013;<lpage>1392</lpage>.<pub-id pub-id-type="pmid">32068150</pub-id>
</mixed-citation></ref><ref id="bibr16-17562848251323004"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Limketkai</surname><given-names>BN</given-names></name>
<name><surname>Godoy-Brewer</surname><given-names>G</given-names></name>
<name><surname>Parian</surname><given-names>AM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Dietary interventions for the treatment of inflammatory bowel diseases: an updated systematic review and meta-analysis</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2023</year>; <volume>21</volume>(<issue>10</issue>): 2508&#x02013;2525.e10.</mixed-citation></ref><ref id="bibr17-17562848251323004"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jagt</surname><given-names>JZ</given-names></name>
<name><surname>van Rheenen</surname><given-names>PF</given-names></name>
<name><surname>Thoma</surname><given-names>SMA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership</article-title>. <source>Lancet Gastroenterol Hepatol</source>
<year>2023</year>; <volume>8</volume>(<issue>8</issue>): <fpage>690</fpage>&#x02013;<lpage>691</lpage>.<pub-id pub-id-type="pmid">37230110</pub-id>
</mixed-citation></ref><ref id="bibr18-17562848251323004"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Grant</surname><given-names>A</given-names></name>
<name><surname>Crane</surname><given-names>M</given-names></name>
<name><surname>Laupacis</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Engaging patients and caregivers in research for pediatric inflammatory bowel disease: top 10 research priorities</article-title>. <source>J Pediatr Gastroenterol Nutr</source>
<year>2019</year>; <volume>69</volume>(<issue>3</issue>): <fpage>317</fpage>&#x02013;<lpage>323</lpage>.<pub-id pub-id-type="pmid">31436670</pub-id>
</mixed-citation></ref><ref id="bibr19-17562848251323004"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>H</given-names></name>
<name><surname>Minozzi</surname><given-names>S</given-names></name>
<name><surname>Kopylov</surname><given-names>U</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>ECCO guidelines on therapeutics in Crohn&#x02019;s disease: medical treatment</article-title>. <source>J Crohns Colitis</source>
<year>2024</year>; <volume>18</volume>(<issue>10</issue>): <fpage>1531</fpage>&#x02013;<lpage>1555</lpage>.<pub-id pub-id-type="pmid">38877997</pub-id>
</mixed-citation></ref><ref id="bibr20-17562848251323004"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van Rheenen</surname><given-names>PF</given-names></name>
<name><surname>Aloi</surname><given-names>M</given-names></name>
<name><surname>Assa</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The medical management of paediatric Crohn&#x02019;s disease: an ECCO-ESPGHAN guideline update</article-title>. <source>J Crohns Colitis</source>. Epub ahead of print October 2020. DOI: <pub-id pub-id-type="doi">10.1093/ecco-jcc/jjaa161</pub-id>.</mixed-citation></ref><ref id="bibr21-17562848251323004"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bischoff</surname><given-names>SC</given-names></name>
<name><surname>Bager</surname><given-names>P</given-names></name>
<name><surname>Escher</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>ESPEN guideline on clinical nutrition in inflammatory bowel disease</article-title>. <source>Clin Nutr</source>
<year>2023</year>; <volume>42</volume>(<issue>3</issue>): <fpage>352</fpage>&#x02013;<lpage>379</lpage>.<pub-id pub-id-type="pmid">36739756</pub-id>
</mixed-citation></ref><ref id="bibr22-17562848251323004"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ukovic</surname><given-names>B</given-names></name>
<name><surname>Chapman</surname><given-names>B</given-names></name>
<name><surname>Schulberg</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Novel use of the Crohn&#x02019;s disease exclusion diet plus partial enteral nutrition for the treatment of Crohn&#x02019;s disease during pregnancy</article-title>. <source>ACG Case Rep J</source>
<year>2023</year>; <volume>10</volume>(<issue>7</issue>): e01078.</mixed-citation></ref><ref id="bibr23-17562848251323004"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sigall Boneh</surname><given-names>R</given-names></name>
<name><surname>Sarbagili Shabat</surname><given-names>C</given-names></name>
<name><surname>Yanai</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Dietary therapy with the Crohn&#x02019;s disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy</article-title>. <source>J Crohns Colitis</source>
<year>2017</year>; <volume>11</volume>(<issue>10</issue>): <fpage>1205</fpage>&#x02013;<lpage>1212</lpage>.<pub-id pub-id-type="pmid">28525622</pub-id>
</mixed-citation></ref><ref id="bibr24-17562848251323004"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fliss-Isakov</surname><given-names>N</given-names></name>
<name><surname>Aviv Cohen</surname><given-names>N</given-names></name>
<name><surname>Bromberg</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Crohn&#x02019;s disease exclusion diet for the treatment of Crohn&#x02019;s disease: real-world experience from a tertiary center</article-title>. <source>J Clin Med</source>
<year>2023</year>; <volume>12</volume>(<issue>16</issue>): <fpage>5428</fpage>.<pub-id pub-id-type="pmid">37629470</pub-id>
</mixed-citation></ref><ref id="bibr25-17562848251323004"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>DL</given-names></name>
<name><surname>Palmer</surname><given-names>LB</given-names></name>
<name><surname>Nguyen</surname><given-names>ET</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Specialized enteral nutrition therapy in Crohn&#x02019;s disease patients on maintenance infliximab therapy: a meta-analysis</article-title>. <source>Therap Adv Gastroenterol</source>
<year>2015</year>; <volume>8</volume>(<issue>4</issue>): <fpage>168</fpage>&#x02013;<lpage>175</lpage>.</mixed-citation></ref><ref id="bibr26-17562848251323004"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname><given-names>Z</given-names></name>
<name><surname>Ninan</surname><given-names>K</given-names></name>
<name><surname>Johnston</surname><given-names>BC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Microbiota signatures and mucosal healing in the use of enteral nutrition therapy v. corticosteroids for the treatment of children with Crohn&#x02019;s disease: a systematic review and meta-analysis</article-title>. <source>Br J Nutr</source>
<year>2023</year>; <volume>130</volume>(<issue>8</issue>): <fpage>1385</fpage>&#x02013;<lpage>1402</lpage>.<pub-id pub-id-type="pmid">36788671</pub-id>
</mixed-citation></ref><ref id="bibr27-17562848251323004"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sohouli</surname><given-names>MH</given-names></name>
<name><surname>Fatahi</surname><given-names>S</given-names></name>
<name><surname>Farahmand</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn&#x02019;s disease</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2022</year>; <volume>56</volume>(<issue>3</issue>): <fpage>384</fpage>&#x02013;<lpage>395</lpage>.<pub-id pub-id-type="pmid">35748390</pub-id>
</mixed-citation></ref><ref id="bibr28-17562848251323004"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Krasnovsky</surname><given-names>L</given-names></name>
<name><surname>Weber</surname><given-names>AT</given-names></name>
<name><surname>Gershuni</surname><given-names>V</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Preoperative exclusive enteral nutrition is associated with reduced skin and soft tissue and intra-abdominal infections in patients with Crohn&#x02019;s disease undergoing intestinal surgery: results from a meta-analysis</article-title>. <source>Inflamm Bowel Dis</source>
<year>2024</year>; <volume>30</volume>(<issue>11</issue>): <fpage>2105</fpage>&#x02013;<lpage>2114</lpage>.<pub-id pub-id-type="pmid">38262631</pub-id>
</mixed-citation></ref><ref id="bibr29-17562848251323004"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Levine</surname><given-names>A</given-names></name>
<name><surname>Wine</surname><given-names>E</given-names></name>
<name><surname>Assa</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Crohn&#x02019;s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial</article-title>. <source>Gastroenterology</source>
<year>2019</year>; <volume>157</volume>(<issue>2</issue>): 440&#x02013;450.e8.</mixed-citation></ref><ref id="bibr30-17562848251323004"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yanai</surname><given-names>H</given-names></name>
<name><surname>Levine</surname><given-names>A</given-names></name>
<name><surname>Hirsch</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The Crohn&#x02019;s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn&#x02019;s disease (CDED-AD): an open-label, pilot, randomised trial</article-title>. <source>Lancet Gastroenterol Hepatol</source>
<year>2022</year>; <volume>7</volume>(<issue>1</issue>): <fpage>49</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">34739863</pub-id>
</mixed-citation></ref><ref id="bibr31-17562848251323004"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Verburgt</surname><given-names>CM</given-names></name>
<name><surname>Ghiboub</surname><given-names>M</given-names></name>
<name><surname>Benninga</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Nutritional therapy strategies in pediatric Crohn&#x02019;s disease</article-title>. <source>Nutrients</source>
<year>2021</year>; <volume>13</volume>(<issue>1</issue>): <fpage>212</fpage>.<pub-id pub-id-type="pmid">33450982</pub-id>
</mixed-citation></ref><ref id="bibr32-17562848251323004"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Logan</surname><given-names>M</given-names></name>
<name><surname>Gkikas</surname><given-names>K</given-names></name>
<name><surname>Svolos</surname><given-names>V</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn&#x02019;s disease-new insights into dietary disease triggers</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2020</year>; <volume>51</volume>(<issue>10</issue>): <fpage>935</fpage>&#x02013;<lpage>947</lpage>.<pub-id pub-id-type="pmid">32249975</pub-id>
</mixed-citation></ref><ref id="bibr33-17562848251323004"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Logan</surname><given-names>M</given-names></name>
<name><surname>Clark</surname><given-names>CM</given-names></name>
<name><surname>Ijaz</surname><given-names>UZ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2019</year>; <volume>50</volume>(<issue>6</issue>): <fpage>664</fpage>&#x02013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">31342536</pub-id>
</mixed-citation></ref><ref id="bibr34-17562848251323004"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sigall Boneh</surname><given-names>R</given-names></name>
<name><surname>Westoby</surname><given-names>C</given-names></name>
<name><surname>Oseran</surname><given-names>I</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The Crohn&#x02019;s disease exclusion diet: a comprehensive review of evidence, implementation strategies, practical guidance, and future directions</article-title>. <source>Inflamm Bowel Dis</source>
<year>2024</year>; <volume>30</volume>(<issue>10</issue>): <fpage>1888</fpage>&#x02013;<lpage>1902</lpage>.<pub-id pub-id-type="pmid">37978895</pub-id>
</mixed-citation></ref><ref id="bibr35-17562848251323004"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Van Limbergen</surname><given-names>J</given-names></name>
<name><surname>Haskett</surname><given-names>J</given-names></name>
<name><surname>Griffiths</surname><given-names>AM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Toward enteral nutrition for the treatment of pediatric Crohn disease in Canada: a workshop to identify barriers and enablers</article-title>. <source>Can J Gastroenterol Hepatol</source>
<year>2015</year>; <volume>29</volume>(<issue>7</issue>): <fpage>351</fpage>&#x02013;<lpage>356</lpage>.<pub-id pub-id-type="pmid">26076398</pub-id>
</mixed-citation></ref><ref id="bibr36-17562848251323004"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ghiboub</surname><given-names>M</given-names></name>
<name><surname>Penny</surname><given-names>S</given-names></name>
<name><surname>Verburgt</surname><given-names>CM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Metabolome changes with diet-induced remission in pediatric Crohn&#x02019;s disease</article-title>. <source>Gastroenterology</source>
<year>2022</year>; <volume>163</volume>(<issue>4</issue>): 922&#x02013;936.e15.</mixed-citation></ref><ref id="bibr37-17562848251323004"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Miyamoto</surname><given-names>K</given-names></name>
<name><surname>Sujino</surname><given-names>T</given-names></name>
<name><surname>Kanai</surname><given-names>T</given-names></name>
</person-group>. <article-title>The tryptophan metabolic pathway of the microbiome and host cells in health and disease</article-title>. <source>Int Immunol</source>
<year>2024</year>; <volume>36</volume>(<issue>12</issue>): <fpage>601</fpage>&#x02013;<lpage>616</lpage>.<pub-id pub-id-type="pmid">38869080</pub-id>
</mixed-citation></ref><ref id="bibr38-17562848251323004"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Agus</surname><given-names>A</given-names></name>
<name><surname>Planchais</surname><given-names>J</given-names></name>
<name><surname>Sokol</surname><given-names>H</given-names></name>
</person-group>. <article-title>Gut microbiota regulation of tryptophan metabolism in health and disease</article-title>. <source>Cell Host Microbe</source>
<year>2018</year>; <volume>23</volume>(<issue>6</issue>): <fpage>716</fpage>&#x02013;<lpage>724</lpage>.<pub-id pub-id-type="pmid">29902437</pub-id>
</mixed-citation></ref><ref id="bibr39-17562848251323004"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Suarez</surname><given-names>RG</given-names></name>
<name><surname>Guruprasad</surname><given-names>N</given-names></name>
<name><surname>Tata</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Serum metabolites relate to mucosal and transmural inflammation in pediatric Crohn disease</article-title>. <source>J Crohns Colitis</source>
<year>2024</year>; <volume>18</volume>(<issue>11</issue>): <fpage>1832</fpage>&#x02013;<lpage>1844</lpage>.<pub-id pub-id-type="pmid">38842257</pub-id>
</mixed-citation></ref><ref id="bibr40-17562848251323004"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bosch</surname><given-names>S</given-names></name>
<name><surname>Struys</surname><given-names>EA</given-names></name>
<name><surname>van Gaal</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Fecal amino acid analysis can discriminate de novo treatment-naive pediatric inflammatory bowel disease from controls</article-title>. <source>J Pediatr Gastroenterol Nutr</source>
<year>2018</year>; <volume>66</volume>(<issue>5</issue>): <fpage>773</fpage>&#x02013;<lpage>778</lpage>.<pub-id pub-id-type="pmid">29112087</pub-id>
</mixed-citation></ref><ref id="bibr41-17562848251323004"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jagt</surname><given-names>JZ</given-names></name>
<name><surname>Struys</surname><given-names>EA</given-names></name>
<name><surname>Ayada</surname><given-names>I</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Fecal amino acid analysis in newly diagnosed pediatric inflammatory bowel disease: a multicenter case-control study</article-title>. <source>Inflamm Bowel Dis</source>
<year>2022</year>; <volume>28</volume>(<issue>5</issue>): <fpage>755</fpage>&#x02013;<lpage>763</lpage>.<pub-id pub-id-type="pmid">34757415</pub-id>
</mixed-citation></ref><ref id="bibr42-17562848251323004"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ghiboub</surname><given-names>M</given-names></name>
<name><surname>Boneh</surname><given-names>RS</given-names></name>
<name><surname>Sovran</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Sustained diet-induced remission in pediatric Crohn&#x02019;s disease is associated with kynurenine and serotonin pathways</article-title>. <source>Inflamm Bowel Dis</source>
<year>2023</year>; <volume>29</volume>(<issue>5</issue>): <fpage>684</fpage>&#x02013;<lpage>694</lpage>.<pub-id pub-id-type="pmid">36637175</pub-id>
</mixed-citation></ref><ref id="bibr43-17562848251323004"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ghiboub</surname><given-names>M</given-names></name>
<name><surname>Verburgt</surname><given-names>CM</given-names></name>
<name><surname>Sovran</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Nutritional therapy to modulate tryptophan metabolism and aryl hydrocarbon-receptor signaling activation in human diseases</article-title>. <source>Nutrients</source>
<year>2020</year>; <volume>12</volume>(<issue>9</issue>): <fpage>2846</fpage>.<pub-id pub-id-type="pmid">32957545</pub-id>
</mixed-citation></ref><ref id="bibr44-17562848251323004"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nikolaus</surname><given-names>S</given-names></name>
<name><surname>Schulte</surname><given-names>B</given-names></name>
<name><surname>Al-Massad</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases</article-title>. <source>Gastroenterology</source>
<year>2017</year>; <volume>153</volume>(<issue>6</issue>): 1504&#x02013;1516.e2.</mixed-citation></ref><ref id="bibr45-17562848251323004"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Harris</surname><given-names>DMM</given-names></name>
<name><surname>Szymczak</surname><given-names>S</given-names></name>
<name><surname>Schuchardt</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Tryptophan degradation as a systems phenomenon in inflammation&#x02014;an analysis across 13 chronic inflammatory diseases</article-title>. <source>EBioMedicine</source>
<year>2024</year>; <volume>102</volume>: <fpage>105056</fpage>.<pub-id pub-id-type="pmid">38471395</pub-id>
</mixed-citation></ref><ref id="bibr46-17562848251323004"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname><given-names>F</given-names></name>
<name><surname>Du</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Association between metabolites in tryptophan-kynurenine pathway and inflammatory bowel disease: a two-sample Mendelian randomization</article-title>. <source>Sci Rep</source>
<year>2024</year>; <volume>14</volume>(<issue>1</issue>): <fpage>201</fpage>.<pub-id pub-id-type="pmid">38167867</pub-id>
</mixed-citation></ref><ref id="bibr47-17562848251323004"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wolf</surname><given-names>AM</given-names></name>
<name><surname>Wolf</surname><given-names>D</given-names></name>
<name><surname>Rumpold</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease</article-title>. <source>Clin Immunol</source>
<year>2004</year>; <volume>113</volume>(<issue>1</issue>): <fpage>47</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">15380529</pub-id>
</mixed-citation></ref><ref id="bibr48-17562848251323004"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sigall Boneh</surname><given-names>R</given-names></name>
<name><surname>Van Limbergen</surname><given-names>J</given-names></name>
<name><surname>Wine</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Dietary therapies induce rapid response and remission in pediatric patients with active Crohn&#x02019;s disease</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2021</year>; <volume>19</volume>(<issue>4</issue>): <fpage>752</fpage>&#x02013;<lpage>759</lpage>.<pub-id pub-id-type="pmid">32302709</pub-id>
</mixed-citation></ref><ref id="bibr49-17562848251323004"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Truyens</surname><given-names>M</given-names></name>
<name><surname>Lobat&#x000f3;n</surname><given-names>T</given-names></name>
<name><surname>Ferrante</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of 5-hydroxytryptophan on fatigue in quiescent inflammatory bowel disease: a randomized controlled trial</article-title>. <source>Gastroenterology</source>
<year>2022</year>; <volume>163</volume>(<issue>5</issue>): 1294&#x02013;1305.e3.</mixed-citation></ref><ref id="bibr50-17562848251323004"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bager</surname><given-names>P</given-names></name>
<name><surname>Hvas</surname><given-names>CL</given-names></name>
<name><surname>Rud</surname><given-names>CL</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2021</year>; <volume>53</volume>(<issue>1</issue>): <fpage>79</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">33210299</pub-id>
</mixed-citation></ref><ref id="bibr51-17562848251323004"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Torki</surname><given-names>M</given-names></name>
<name><surname>Gholamrezaei</surname><given-names>A</given-names></name>
<name><surname>Mirbagher</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Vitamin D deficiency associated with disease activity in patients with inflammatory bowel diseases</article-title>. <source>Dig Dis Sci</source>
<year>2015</year>; <volume>60</volume>(<issue>10</issue>): <fpage>3085</fpage>&#x02013;<lpage>3091</lpage>.<pub-id pub-id-type="pmid">26031421</pub-id>
</mixed-citation></ref><ref id="bibr52-17562848251323004"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Verburgt</surname><given-names>CM</given-names></name>
<name><surname>Dunn</surname><given-names>KA</given-names></name>
<name><surname>Ghiboub</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Successful dietary therapy in paediatric Crohn&#x02019;s disease is associated with shifts in bacterial dysbiosis and inflammatory metabotype towards healthy controls</article-title>. <source>J Crohns Colitis</source>
<year>2023</year>; <volume>17</volume>(<issue>1</issue>): <fpage>61</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">36106847</pub-id>
</mixed-citation></ref><ref id="bibr53-17562848251323004"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Alarcan</surname><given-names>H</given-names></name>
<name><surname>Chaumond</surname><given-names>R</given-names></name>
<name><surname>Emond</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Some CSF kynurenine pathway intermediates associated with disease evolution in amyotrophic lateral sclerosis</article-title>. <source>Biomolecules</source>
<year>2021</year>; <volume>11</volume>(<issue>5</issue>): <fpage>691</fpage>.<pub-id pub-id-type="pmid">34063031</pub-id>
</mixed-citation></ref><ref id="bibr54-17562848251323004"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vich Vila</surname><given-names>A</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases</article-title>. <source>Gut</source>
<year>2024</year>; <volume>73</volume>(<issue>11</issue>): <fpage>1909</fpage>&#x02013;<lpage>1920</lpage>.<pub-id pub-id-type="pmid">39002973</pub-id>
</mixed-citation></ref><ref id="bibr55-17562848251323004"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xia</surname><given-names>J</given-names></name>
<name><surname>Wishart</surname><given-names>DS</given-names></name>
</person-group>. <article-title>MetPA: a web-based metabolomics tool for pathway analysis and visualization</article-title>. <source>Bioinformatics</source>
<year>2010</year>; <volume>26</volume>(<issue>18</issue>): <fpage>2342</fpage>&#x02013;<lpage>2344</lpage>.<pub-id pub-id-type="pmid">20628077</pub-id>
</mixed-citation></ref><ref id="bibr56-17562848251323004"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hackstadt</surname><given-names>AJ</given-names></name>
<name><surname>Hess</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Filtering for increased power for microarray data analysis</article-title>. <source>BMC Bioinformatics</source>
<year>2009</year>; <volume>10</volume>: <fpage>11</fpage>.<pub-id pub-id-type="pmid">19133141</pub-id>
</mixed-citation></ref><ref id="bibr57-17562848251323004"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xia</surname><given-names>J</given-names></name>
<name><surname>Broadhurst</surname><given-names>DI</given-names></name>
<name><surname>Wilson</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Translational biomarker discovery in clinical metabolomics: an introductory tutorial</article-title>. <source>Metabolomics</source>
<year>2013</year>; <volume>9</volume>(<issue>2</issue>): <fpage>280</fpage>&#x02013;<lpage>299</lpage>.<pub-id pub-id-type="pmid">23543913</pub-id>
</mixed-citation></ref><ref id="bibr58-17562848251323004"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bossuyt</surname><given-names>PM</given-names></name>
<name><surname>Reitsma</surname><given-names>JB</given-names></name>
<name><surname>Bruns</surname><given-names>DE</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies</article-title>. <source>BMJ</source>
<year>2015</year>; <volume>351</volume>: h5527.</mixed-citation></ref><ref id="bibr59-17562848251323004"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>B</given-names></name>
<name><surname>Hu</surname><given-names>Y</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>New insights into gut-bacteria-derived indole and its derivatives in intestinal and liver diseases</article-title>. <source>Front Pharmacol</source>
<year>2021</year>; <volume>12</volume>: <fpage>769501</fpage>.<pub-id pub-id-type="pmid">34966278</pub-id>
</mixed-citation></ref><ref id="bibr60-17562848251323004"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bolte</surname><given-names>LA</given-names></name>
<name><surname>Vich Vila</surname><given-names>A</given-names></name>
<name><surname>Imhann</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome</article-title>. <source>Gut</source>
<year>2021</year>; <volume>70</volume>(<issue>7</issue>): <fpage>1287</fpage>&#x02013;<lpage>1298</lpage>.<pub-id pub-id-type="pmid">33811041</pub-id>
</mixed-citation></ref><ref id="bibr61-17562848251323004"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Turpin</surname><given-names>W</given-names></name>
<name><surname>Dong</surname><given-names>M</given-names></name>
<name><surname>Sasson</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Mediterranean-like dietary pattern associations with gut microbiome composition and subclinical gastrointestinal inflammation</article-title>. <source>Gastroenterology</source>
<year>2022</year>; <volume>163</volume>(<issue>3</issue>): <fpage>685</fpage>&#x02013;<lpage>698</lpage>.<pub-id pub-id-type="pmid">35643175</pub-id>
</mixed-citation></ref><ref id="bibr62-17562848251323004"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Raygoza Garay</surname><given-names>JA</given-names></name>
<name><surname>Turpin</surname><given-names>W</given-names></name>
<name><surname>Lee</surname><given-names>SH</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Gut microbiome composition is associated with future onset of Crohn&#x02019;s disease in healthy first-degree relatives</article-title>. <source>Gastroenterology</source>
<year>2023</year>; <volume>165</volume>(<issue>3</issue>): <fpage>670</fpage>&#x02013;<lpage>681</lpage>.<pub-id pub-id-type="pmid">37263307</pub-id>
</mixed-citation></ref><ref id="bibr63-17562848251323004"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sabino</surname><given-names>J</given-names></name>
<name><surname>Tarassishin</surname><given-names>L</given-names></name>
<name><surname>Eisele</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Influence of early life factors, including breast milk composition, on the microbiome of infants born to mothers with and without inflammatory bowel disease</article-title>. <source>J Crohns Colitis</source>
<year>2023</year>; <volume>17</volume>(<issue>11</issue>): <fpage>1723</fpage>&#x02013;<lpage>1732</lpage>.<pub-id pub-id-type="pmid">37279927</pub-id>
</mixed-citation></ref><ref id="bibr64-17562848251323004"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>ES</given-names></name>
<name><surname>Tarassishin</surname><given-names>L</given-names></name>
<name><surname>Eisele</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Longitudinal changes in fecal calprotectin levels among pregnant women with and without inflammatory bowel disease and their babies</article-title>. <source>Gastroenterology</source>
<year>2021</year>; <volume>160</volume>(<issue>4</issue>): 1118&#x02013;1130.e3.</mixed-citation></ref><ref id="bibr65-17562848251323004"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dennison</surname><given-names>TW</given-names></name>
<name><surname>Edgar</surname><given-names>RD</given-names></name>
<name><surname>Payne</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn&#x02019;s disease</article-title>. <source>Gut</source>
<year>2024</year>; <volume>73</volume>(<issue>9</issue>): <fpage>1464</fpage>&#x02013;<lpage>1477</lpage>.<pub-id pub-id-type="pmid">38857990</pub-id>
</mixed-citation></ref><ref id="bibr66-17562848251323004"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Klomberg</surname><given-names>RCW</given-names></name>
<name><surname>Hellendoorn</surname><given-names>AE</given-names></name>
<name><surname>Kemos</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Rare and severe adverse events in children with inflammatory bowel disease: analysis of data from the PIBD-SETQuality Safety Registry</article-title>. <source>Lancet Child Adolesc Health</source>
<year>2024</year>; <volume>8</volume>(<issue>6</issue>): <fpage>422</fpage>&#x02013;<lpage>432</lpage>.<pub-id pub-id-type="pmid">38697175</pub-id>
</mixed-citation></ref><ref id="bibr67-17562848251323004"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kerbiriou</surname><given-names>C</given-names></name>
<name><surname>Dickson</surname><given-names>C</given-names></name>
<name><surname>Nichols</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Treatment of active Crohn&#x02019;s disease with exclusive enteral nutrition diminishes the immunostimulatory potential of fecal microbial products</article-title>. <source>Inflamm Bowel Dis</source>
<year>2024</year>; <volume>30</volume>(<issue>12</issue>): <fpage>2457</fpage>&#x02013;<lpage>2466</lpage>.<pub-id pub-id-type="pmid">38982655</pub-id>
</mixed-citation></ref><ref id="bibr68-17562848251323004"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jongsma</surname><given-names>MME</given-names></name>
<name><surname>Vuijk</surname><given-names>SA</given-names></name>
<name><surname>Cozijnsen</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn&#x02019;s disease</article-title>. <source>Eur J Pediatr</source>
<year>2022</year>; <volume>181</volume>(<issue>8</issue>): <fpage>3055</fpage>&#x02013;<lpage>3065</lpage>.<pub-id pub-id-type="pmid">35672586</pub-id>
</mixed-citation></ref><ref id="bibr69-17562848251323004"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>B</given-names></name>
<name><surname>Curle</surname><given-names>J</given-names></name>
<name><surname>Gervais</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Exclusive enteral nutrition impacts peripheral blood mononuclear cell profile of children with Crohn&#x02019;s disease</article-title>. <source>J Pediatr Gastroenterol Nutr</source>
<year>2024</year>; <volume>79</volume>(<issue>1</issue>): <fpage>148</fpage>&#x02013;<lpage>153</lpage>.<pub-id pub-id-type="pmid">38779951</pub-id>
</mixed-citation></ref><ref id="bibr70-17562848251323004"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jongsma</surname><given-names>MME</given-names></name>
<name><surname>Aardoom</surname><given-names>MA</given-names></name>
<name><surname>Cozijnsen</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn&#x02019;s disease: an open-label multicentre randomised controlled trial</article-title>. <source>Gut</source>
<year>2022</year>; <volume>71</volume>(<issue>1</issue>): <fpage>34</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">33384335</pub-id>
</mixed-citation></ref><ref id="bibr71-17562848251323004"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Stournaras</surname><given-names>E</given-names></name>
<name><surname>Qian</surname><given-names>W</given-names></name>
<name><surname>Pappas</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn&#x02019;s disease: long-term outcomes for 11&#x02009;928 patients in the UK inflammatory bowel disease bioresource</article-title>. <source>Gut</source>
<year>2021</year>; <volume>70</volume>(<issue>4</issue>): <fpage>677</fpage>&#x02013;<lpage>686</lpage>.<pub-id pub-id-type="pmid">33004550</pub-id>
</mixed-citation></ref><ref id="bibr72-17562848251323004"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yanai</surname><given-names>H</given-names></name>
<name><surname>Goren</surname><given-names>I</given-names></name>
<name><surname>Godny</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Early indolent course of Crohn&#x02019;s disease in newly diagnosed patients is not rare and possibly predictable</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2021</year>; <volume>19</volume>(<issue>8</issue>): 1564&#x02013;1572.e5.</mixed-citation></ref><ref id="bibr73-17562848251323004"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nichols</surname><given-names>B</given-names></name>
<name><surname>Briola</surname><given-names>A</given-names></name>
<name><surname>Logan</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Gut metabolome and microbiota signatures predict response to treatment with exclusive enteral nutrition in a prospective study in children with active Crohn&#x02019;s disease</article-title>. <source>Am J Clin Nutr</source>
<year>2024</year>; <volume>119</volume>(<issue>4</issue>): <fpage>885</fpage>&#x02013;<lpage>895</lpage>.<pub-id pub-id-type="pmid">38569785</pub-id>
</mixed-citation></ref><ref id="bibr74-17562848251323004"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dijk</surname><given-names>S</given-names></name>
<name><surname>Jarman</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pre-diagnosis diet predicts response to exclusive enteral nutrition and correlates with microbiome in pediatric Crohn disease</article-title>. <source>Nutrients</source>
<year>2024</year>; <volume>16</volume>(<issue>7</issue>): <fpage>1033</fpage>.<pub-id pub-id-type="pmid">38613066</pub-id>
</mixed-citation></ref><ref id="bibr75-17562848251323004"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>D</given-names></name>
<name><surname>Baldassano</surname><given-names>RN</given-names></name>
<name><surname>Otley</surname><given-names>AR</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn&#x02019;s disease</article-title>. <source>Inflamm Bowel Dis</source>
<year>2015</year>; <volume>21</volume>(<issue>8</issue>): <fpage>1786</fpage>&#x02013;<lpage>1793</lpage>.<pub-id pub-id-type="pmid">25970545</pub-id>
</mixed-citation></ref><ref id="bibr76-17562848251323004"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>T</given-names></name>
<name><surname>Macdonald</surname><given-names>S</given-names></name>
<name><surname>Hill</surname><given-names>SM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Treatment of active Crohn&#x02019;s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial</article-title>. <source>Gut</source>
<year>2006</year>; <volume>55</volume>(<issue>3</issue>): <fpage>356</fpage>&#x02013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">16162683</pub-id>
</mixed-citation></ref><ref id="bibr77-17562848251323004"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JF</given-names></name>
<name><surname>Korevaar</surname><given-names>DA</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration</article-title>. <source>BMJ Open</source>
<year>2016</year>; <volume>6</volume>(<issue>11</issue>): e012799.</mixed-citation></ref><ref id="bibr78-17562848251323004"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wilschanski</surname><given-names>M</given-names></name>
<name><surname>Sherman</surname><given-names>P</given-names></name>
<name><surname>Pencharz</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Supplementary enteral nutrition maintains remission in paediatric Crohn&#x02019;s disease</article-title>. <source>Gut</source>
<year>1996</year>; <volume>38</volume>(<issue>4</issue>): <fpage>543</fpage>&#x02013;<lpage>548</lpage>.<pub-id pub-id-type="pmid">8707085</pub-id>
</mixed-citation></ref><ref id="bibr79-17562848251323004"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Afzal</surname><given-names>NA</given-names></name>
<name><surname>Davies</surname><given-names>S</given-names></name>
<name><surname>Paintin</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Colonic Crohn&#x02019;s disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved</article-title>. <source>Dig Dis Sci</source>
<year>2005</year>; <volume>50</volume>(<issue>8</issue>): <fpage>1471</fpage>&#x02013;<lpage>1475</lpage>.<pub-id pub-id-type="pmid">16110838</pub-id>
</mixed-citation></ref><ref id="bibr80-17562848251323004"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dhaliwal</surname><given-names>J</given-names></name>
<name><surname>Carroll</surname><given-names>MW</given-names></name>
<name><surname>deBruyn</surname><given-names>JC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The phenotypic spectrum of new-onset IBD in Canadian Children of South Asian Ethnicity: a prospective multi-centre comparative study</article-title>. <source>J Crohns Colitis</source>
<year>2022</year>; <volume>16</volume>(<issue>2</issue>): <fpage>216</fpage>&#x02013;<lpage>223</lpage>.<pub-id pub-id-type="pmid">34379117</pub-id>
</mixed-citation></ref><ref id="bibr81-17562848251323004"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Allez</surname><given-names>M</given-names></name>
<name><surname>Lemann</surname><given-names>M</given-names></name>
<name><surname>Bonnet</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Long term outcome of patients with active Crohn&#x02019;s disease exhibiting extensive and deep ulcerations at colonoscopy</article-title>. <source>Am J Gastroenterol</source>
<year>2002</year>; <volume>97</volume>(<issue>4</issue>): <fpage>947</fpage>&#x02013;<lpage>953</lpage>.<pub-id pub-id-type="pmid">12003431</pub-id>
</mixed-citation></ref><ref id="bibr82-17562848251323004"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rivi&#x000e8;re</surname><given-names>P</given-names></name>
<name><surname>D&#x02019;Haens</surname><given-names>G</given-names></name>
<name><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Location but not severity of endoscopic lesions influences endoscopic remission rates in Crohn&#x02019;s disease: a post hoc analysis of TAILORIX</article-title>. <source>Am J Gastroenterol</source>
<year>2021</year>; <volume>116</volume>(<issue>1</issue>): <fpage>134</fpage>&#x02013;<lpage>141</lpage>.<pub-id pub-id-type="pmid">33177349</pub-id>
</mixed-citation></ref><ref id="bibr83-17562848251323004"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ricciuto</surname><given-names>A</given-names></name>
<name><surname>Aardoom</surname><given-names>M</given-names></name>
<name><surname>Orlanski-Meyer</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Predicting outcomes in pediatric Crohn&#x02019;s disease for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program</article-title>. <source>Gastroenterology</source>
<year>2021</year>; <volume>160</volume>(<issue>1</issue>): 403&#x02013;436.e26.</mixed-citation></ref><ref id="bibr84-17562848251323004"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Beaugerie</surname><given-names>L</given-names></name>
<name><surname>Seksik</surname><given-names>P</given-names></name>
<name><surname>Nion-Larmurier</surname><given-names>I</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Predictors of Crohn&#x02019;s disease</article-title>. <source>Gastroenterology</source>
<year>2006</year>; <volume>130</volume>(<issue>3</issue>): <fpage>650</fpage>&#x02013;<lpage>656</lpage>.<pub-id pub-id-type="pmid">16530505</pub-id>
</mixed-citation></ref><ref id="bibr85-17562848251323004"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Atia</surname><given-names>O</given-names></name>
<name><surname>Lujan</surname><given-names>R</given-names></name>
<name><surname>Buchuk</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Predictors of complicated disease course in adults and children with Crohn&#x02019;s disease: a nationwide study from the epi-IIRN</article-title>. <source>Inflamm Bowel Dis</source>
<year>2024</year>; <volume>30</volume>(<issue>12</issue>): <fpage>2370</fpage>&#x02013;<lpage>2379</lpage>.<pub-id pub-id-type="pmid">38330226</pub-id>
</mixed-citation></ref><ref id="bibr86-17562848251323004"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Atia</surname><given-names>O</given-names></name>
<name><surname>Pujol-Muncunill</surname><given-names>G</given-names></name>
<name><surname>Navas-L&#x000f3;pez</surname><given-names>VM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2022</year>; <volume>56</volume>(<issue>5</issue>): <fpage>794</fpage>&#x02013;<lpage>801</lpage>.<pub-id pub-id-type="pmid">35735987</pub-id>
</mixed-citation></ref><ref id="bibr87-17562848251323004"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Atia</surname><given-names>O</given-names></name>
<name><surname>Kang</surname><given-names>B</given-names></name>
<name><surname>Orlansky-Meyer</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Existing prediction models of disease course in paediatric Crohn&#x02019;s disease are poorly replicated in a prospective inception cohort</article-title>. <source>J Crohns Colitis</source>
<year>2022</year>; <volume>16</volume>(<issue>7</issue>): <fpage>1039</fpage>&#x02013;<lpage>1048</lpage>.<pub-id pub-id-type="pmid">35020870</pub-id>
</mixed-citation></ref><ref id="bibr88-17562848251323004"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ricciuto</surname><given-names>A</given-names></name>
<name><surname>Mack</surname><given-names>DR</given-names></name>
<name><surname>Huynh</surname><given-names>HQ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Diagnostic delay is associated with complicated disease and growth impairment in paediatric Crohn&#x02019;s disease</article-title>. <source>J Crohns Colitis</source>
<year>2021</year>; <volume>15</volume>(<issue>3</issue>): <fpage>419</fpage>&#x02013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">32978629</pub-id>
</mixed-citation></ref><ref id="bibr89-17562848251323004"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Noor</surname><given-names>NM</given-names></name>
<name><surname>Lee</surname><given-names>JC</given-names></name>
<name><surname>Bond</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn&#x02019;s disease (PROFILE): a multicentre, open-label randomised controlled trial</article-title>. <source>Lancet Gastroenterol Hepatol</source>
<year>2024</year>; <volume>9</volume>(<issue>5</issue>): <fpage>415</fpage>&#x02013;<lpage>427</lpage>.<pub-id pub-id-type="pmid">38402895</pub-id>
</mixed-citation></ref><ref id="bibr90-17562848251323004"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Satsangi</surname><given-names>J</given-names></name>
<name><surname>Nowak</surname><given-names>J</given-names></name>
<name><surname>Kalla</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Treatment strategies and biomarkers in Crohn&#x02019;s disease: the PROFILE trial</article-title>. <source>Lancet Gastroenterol Hepatol</source>
<year>2024</year>; <volume>9</volume>(<issue>7</issue>): <fpage>591</fpage>&#x02013;<lpage>592</lpage>.</mixed-citation></ref><ref id="bibr91-17562848251323004"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Aden</surname><given-names>K</given-names></name>
<name><surname>Rehman</surname><given-names>A</given-names></name>
<name><surname>Waschina</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases</article-title>. <source>Gastroenterology</source>
<year>2019</year>; <volume>157</volume>(<issue>5</issue>): 1279&#x02013;1292.e11.</mixed-citation></ref><ref id="bibr92-17562848251323004"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Albenberg</surname><given-names>L</given-names></name>
<name><surname>Brensinger</surname><given-names>CM</given-names></name>
<name><surname>Wu</surname><given-names>Q</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>A diet low in red and processed meat does not reduce rate of Crohn&#x02019;s disease flares</article-title>. <source>Gastroenterology</source>
<year>2019</year>; <volume>157</volume>(<issue>1</issue>): 128&#x02013;136.e5.</mixed-citation></ref><ref id="bibr93-17562848251323004"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Armstrong</surname><given-names>HK</given-names></name>
<name><surname>Bording-Jorgensen</surname><given-names>M</given-names></name>
<name><surname>Santer</surname><given-names>DM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Unfermented beta-fructan fibers fuel inflammation in select inflammatory bowel disease patients</article-title>. <source>Gastroenterology</source>
<year>2023</year>; <volume>164</volume>(<issue>2</issue>): <fpage>228</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">36183751</pub-id>
</mixed-citation></ref><ref id="bibr94-17562848251323004"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hezaveh</surname><given-names>K</given-names></name>
<name><surname>Shinde</surname><given-names>RS</given-names></name>
<name><surname>Klotgen</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity</article-title>. <source>Immunity</source>
<year>2022</year>; <volume>55</volume>(<issue>2</issue>): 324&#x02013;340.e8.</mixed-citation></ref><ref id="bibr95-17562848251323004"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Koper</surname><given-names>JE</given-names></name>
<name><surname>Troise</surname><given-names>AD</given-names></name>
<name><surname>Loonen</surname><given-names>LM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Tryptophan supplementation increases the production of microbial-derived AhR agonists in an in vitro simulator of intestinal microbial ecosystem</article-title>. <source>J Agric Food Chem</source>
<year>2022</year>; <volume>70</volume>(<issue>13</issue>): <fpage>3958</fpage>&#x02013;<lpage>3968</lpage>.<pub-id pub-id-type="pmid">35344652</pub-id>
</mixed-citation></ref><ref id="bibr96-17562848251323004"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Badawy</surname><given-names>AA</given-names></name>
<name><surname>Dawood</surname><given-names>S</given-names></name>
</person-group>. <article-title>Molecular Insights into the Interaction of Tryptophan Metabolites with the Human Aryl Hydrocarbon Receptor in Silico: Tryptophan as Antagonist and no Direct Involvement of Kynurenine</article-title>. <source>Front Biosci</source> (Landmark Ed) <year>2024</year>; <volume>29</volume>(<issue>9</issue>): <fpage>333</fpage>. doi: 10.31083/j.fbl2909333.</mixed-citation></ref><ref id="bibr97-17562848251323004"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rueda</surname><given-names>GH</given-names></name>
<name><surname>Causada-Calo</surname><given-names>N</given-names></name>
<name><surname>Borojevic</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Oral tryptophan activates duodenal aryl hydrocarbon receptor in healthy subjects: a crossover randomized controlled trial</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>
<year>2024</year>; <volume>326</volume>(<issue>6</issue>): G687&#x02013;G696.</mixed-citation></ref><ref id="bibr98-17562848251323004"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hou</surname><given-names>JJ</given-names></name>
<name><surname>Ma</surname><given-names>AH</given-names></name>
<name><surname>Qin</surname><given-names>YH</given-names></name>
</person-group>. <article-title>Activation of the aryl hydrocarbon receptor in inflammatory bowel disease: insights from gut microbiota</article-title>. <source>Front Cell Infect Microbiol</source>
<year>2023</year>; <volume>13</volume>: <fpage>1279172</fpage>.<pub-id pub-id-type="pmid">37942478</pub-id>
</mixed-citation></ref></ref-list></back></article>